Zomedica (ZOM) 10-K 1 Mar 22 2022 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Feb. 25, 2022	Jun. 30, 2021
Cover [Abstract]
Entity Registrant Name	ZOMEDICA CORP.
Entity Central Index Key	0001684144
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		979,899,668
Entity Public Float			$ 803.2
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-38298
Entity Incorporation State Country Code	Z4
Entity Interactive Data Current	Yes
Icfr Auditor Attestation Flag	true
Entity Address Address Line 1	100 Phoenix Drive
Entity Address Address Line 2	Suite 125
Entity Address City Or Town	Ann Arbor
Entity Address State Or Province	MI
Entity Address Postal Zip Code	48108
Local Phone Number	369-2555
City Area Code	734
Security 12b Title	Common Shares, without par value
Trading Symbol	ZOM
Security Exchange Name	NYSE
Auditor Firm Id	248
Auditor Name	GRANT THORNTON LLP
Auditor Location	Cincinnati, Ohio

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 194,952,208	$ 61,991,703
Inventory, net	2,847,985	0
Prepaid expenses and deposits	1,841,814	1,727,814
Trade receivables, net	315,418	0
Other receivables	450,081	146,207
Total current assets	200,407,506	63,865,724
Prepaid expenses and deposits	394,106	13,924
Property and equipment	1,205,546	583,007
Right-of-use asset	1,319,810	1,318,716
Goodwill	43,287,765	0
Intangible assets	33,519,560	362,663
Other assets	265,000
Total assets	280,399,293	66,144,034
Current liabilities:
Accounts payable and accrued liabilities	3,225,348	1,248,628
Accrued income taxes	239,924	0
Current portion of debt obligation	0	527,360
Current portion of lease obligations	414,695	252,788
Customer contract liabilities	198,112	0
Other current liabilities	261,621	0
Total current liabilities	4,339,700	2,028,776
Lease obligations	964,191	1,087,998
Deferred tax liabilities	3,709,312	0
Customer contract liabilities	139,950	0
Other liabilities	360,797	0
Total liabilities	9,513,950	3,116,774
Mezzanine equity:
Series 1 preferred shares, without par value; 20 shares authorized 0 and 12 series 1 Issued and outstanding at December 31, 2021 and December 31, 2020, respectively	0	11,961,397
Shareholders equity:
Unlimited common shares without par value; 979,899,668 and 642,036,228 Issued and outstanding at December 31, 2021 and December 31, 2020, respectively	380,961,940	104,783,612
Common stock subscribed	0	459,600
Additional paid-in capital	9,313,136	14,792,276
Accumulated deficit	(119,391,398)	(68,969,625)
Accumulated other comprehensive income	1,665	0
Total shareholders' equity	270,885,343	51,065,863
Liabilities and Equity, Total	$ 280,399,293	$ 66,144,034

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Consolidated Balance Sheets
Capital stock, no par value (in dollars per share)	$ 0	$ 0
Capital stock, issued (in shares)	979,899,668	642,036,228
Capital stock, outstanding (in shares)	979,899,668	642,036,228
Preferred stock, no par value (in dollars per share)	$ 0	$ 0
Preferred stock, authorized (in shares)	20	20
Preferred stock, issued (in shares)	0	12
Preferred stock, outstanding (in shares)	0	12

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidated Balance Sheets
Net revenue	$ 4,133,123	$ 0
Cost of revenue	1,079,052	0
Gross profit	3,054,071	0
Expenses:
Research and development	1,672,988	8,043,891
Selling, General and administrative	22,749,080	8,721,087
Loss from operations	(21,367,997)	(16,764,978)
Interest income	(357,447)	32,859
Interest expense	6,054	732
Bad debt expense	6,000	0
Loss on disposal of assets	248,594	121,034
Loss on right-of-use asset	0	59,097
Gain on extinguishment of debt	533,414	0
Other losses (gains)	(51,861)	8,601
Foreign exchange loss	30,301	7,403
Loss before income tax	(20,716,224)	(16,911,784)
Income tax benefit	2,333,054	0
Net loss	(18,383,170)	(16,911,784)
Currency translation adjustment	(1,665)	0
Net comprehensive loss	$ (18,381,505)	$ (16,911,784)
Weighted average number of common shares - basic and diluted	956,533,761	364,444,664
Loss per share - basic and diluted	$ (0.05)	$ (0.05)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)	Total	Series 1 Preferred Stock [Member]	Common Stock	Common Stock Subscribed	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Accumulated other comprehensive loss
Balance, shares at Dec. 31, 2019		12	108,038,398
Balance, amount at Dec. 31, 2019	$ 2,095,459	$ 11,961,397	$ 38,566,820	$ 0	$ 3,625,083	$ (52,057,841)	$ 0
Stock, warrants and prefunded warrant issued for financing, shares			337,830,001
Stock, warrants and prefunded warrant issued for financing, amount	56,496,283	0	$ 32,275,265	0	24,221,018	0	0
Stock issuance costs	(5,107,616)	0	(2,979,594)	0	(2,128,022)	0	0
Placement agent warrants	0	0	(154,767)	0	154,767	0	0
Stock-based compensation	1,656,184	0	$ 0	0	1,656,184	0	0
Stock issued due to exercise of warrants and prefunded warrants, shares			196,167,829
Stock issued due to exercise of warrants and prefunded warrants, amount	24,339,134	0	$ 37,075,888	0	(12,736,754)	0	0
Common stock subscribed	459,600	$ 0	0	459,600	0	0	0
Reclassification to mezzanine equity, shares		(12)
Reclassification to mezzanine equity, amount	(11,961,397)	$ (11,961,397)	0	0	0	0	0
Net loss	$ (16,911,784)	0	$ 0	0	0	(16,911,784)	0
Stock issued due to exercise of stock options, shares	0
Currency translation adjustments	$ 0
Balance, shares at Dec. 31, 2020			642,036,228
Balance, amount at Dec. 31, 2020	51,065,863	0	$ 104,783,612	459,600	14,792,276	(68,969,625)	0
Stock, warrants and prefunded warrant issued for financing, shares			105,013,158
Stock, warrants and prefunded warrant issued for financing, amount	199,525,000	0	$ 199,525,000	0	0	0	0
Stock issuance costs	(14,280,914)	0	(14,280,914)	0	0	0	0
Stock-based compensation	7,092,031	0	0	0	7,092,031	0	0
Common stock subscribed	(459,600)	0	0	(459,600)	0	0	0
Net loss	(18,383,170)	0	$ 0	0	0	(18,383,170)
Stock issued due to exercise of warrants, shares			201,108,405
Stock issued due to exercise of warrants, amount	$ 32,594,610	0	$ 44,114,557	0	(11,519,947)	0	0
Stock issued due to exercise of stock options, shares	7,022,776		7,022,776
Stock issued due to exercise of stock options, amount	$ 1,768,461		$ 2,819,685		(1,051,224)		0
Preferred share exchange, shares			24,719,101
Preferred share exchange, amount	11,961,397	0	$ 44,000,000	0	0	32,038,603	0
Currency translation adjustments	1,665	0	$ 0	0	0		1,665
Balance, shares at Dec. 31, 2021			979,899,668
Balance, amount at Dec. 31, 2021	$ 270,885,343	$ 0	$ 380,961,940	$ 0	$ 9,313,136	$ (119,391,398)	$ 1,665

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (18,383,170)	$ (16,911,784)
Adjustments for
Depreciation	265,496	305,914
Amortization - intangible assets	874,093	224,106
Loss on disposal of property and equipment	248,594	121,034
Loss on other assets	(731)	59,097
Gain on extinguishment of debt	(533,414)	0
Stock-based compensation	7,092,031	1,656,184
Non-cash portion of rent expense	37,738	22,069
Change in non-cash operating working capital, net of acquisition
Inventory	(2,774,484)
Prepaid expenses and deposits	(129,749)	(798,497)
Trade receivables	(47,076)	0
Other receivables	(164,693)	(78,589)
Accounts payable and accrued liabilities	1,412,038	(838,897)
Accrued income tax	196,224	0
Deferred tax liabilities	(2,528,477)	0
Other current liabilities	200,948	0
Customer contract liabilities	6,348	0
Other liabilities	(46,872)	0
Net cash used in operating activities	(14,275,156)	(16,239,363)
Cash flows from investing activities:
Cash from sale of property and equipment	225	20,400
Investment in intangibles	(379,047)	(1,944)
Investment in property and equipment	(147,127)	(14,850)
Cash from lease cancellation or modification	0	1,002,113
Investment in subsidiary acquisition, net of cash acquired	(71,399,419)	0
Net cash (used in) provided by investing activities	(71,925,368)	1,005,719
Cash flows from financing activities:
Proceeds from issuance of common shares, warrants and pre-funded warrants	199,525,000	56,496,283
Cash received from warrant exercises	32,135,010	24,339,134
Cash received from stock option exercises	(1,768,461)	(5,107,616)
Cash received from shares to be issued	0	459,600
Cash paid on stock issuance costs	(14,269,105)	(527,360)
Net cash provided by financing activities	219,159,366	76,714,761
Increase in cash and cash equivalents	132,958,842	61,481,117
Effect of exchange rate changes on cash	1,663	0
Cash and cash equivalents, beginning of period	61,991,703	510,586
Cash and cash equivalents, end of period	194,952,208	61,991,703
Noncash investing and financing activities
Transfer of inventory into property and equipment	798,000	0
Deferred financing fees charge to stock issuance costs	11,810	0
Net equity effect of preferred share exchange	(11,961,397)	0
Supplemental cash flow information:
Interest paid	0	732
Interest received	$ (501,691)	$ (32,353)

Note 1 - Nature of Operations

Note 1 - Nature of Operations	12 Months Ended
	Dec. 31, 2021
Note 1 - Nature of Operations
1. Nature of operation	1. Nature of operations The Company is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. The impact of the novel strain of coronavirus (“COVID-19”) The outbreak of the novel strain of coronavirus, specifically identified as “COVID-19”, resulted in the World Health Organization declaring this virus a global pandemic in March 2020. Governments around the world enacted emergency measures to combat the spread of the virus. These measures included the implementation of travel bans, self-imposed quarantine periods and social distancing. The closure of businesses caused material disruption to businesses resulting in an economic slowdown. Governments and central banks responded with significant monetary and fiscal interventions designed to stabilize the financial markets. The COVID-19 pandemic materially and adversely affected the development and commercialization of our TRUFORMA® platform and the initial five assays. In response to the pandemic, our development partner had reduced the number of employees working in its facilities for a period of time which delayed the completion of the verification of the five initial TRUFORMA® assays and the manufacturing of commercial quantities of the TRUFORMA® platform and the related assays. Veterinary hospitals and clinics that had agreed to participate in the validation of our initial TRUFORMA® assays either shut down for a period of time or limited their operations to those involving only life-threatening conditions, which we have mitigated to a certain extent with our recent ability to successfully complete remote installations. Potential customers have at times restricted access to their facilities which has affected and may continue to affect our ability to perform on-site demonstrations and other marketing activities. The extent to which the COVID-19 pandemic may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the severity of COVID-19, and the effectiveness of governmental actions in response to the pandemic. The emergence of the omicron variant has not caused significant modification to business operations. We continue to install remotely, if potential customers restrict access to their facilities. We intend to continue development of new assays, both for equine indications of our current and planned assays, and for various additional disease states affecting canine, feline, and equine patients in the future.

Note 2 - Basis of Preparation

Note 2 - Basis of Preparation	12 Months Ended
	Dec. 31, 2021
Note 1 - Nature of Operations
2. Basis of preparation	2. Basis of preparation Principles of Consolidation The consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries. Intercompany transactions and balances between consolidated businesses have been eliminated. The accounting policies set out below have been applied consistently in the consolidated financial statements. The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Note 3 - Significant Accounting Policies
3. Significant Accounting Policies	3. Significant accounting policies Estimates and assumptions In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur, and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. Inventories Inventories are stated at the lower of cost or net realizable value. The Company utilizes the specific identification and First in, First out ("FIFO") method to track inventory costs. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles Intangible Assets Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life. Costs related to acquired trademarks, tradename, customer relationships and developed technology have been capitalized and amortized over the estimated useful life. Revenue recognition The Company enters into agreements which may contain multiple promises where customers purchase products, services or a combination thereof. Determining whether products and services are considered distinct performance obligations that should be accounted for separately requires judgment. We determine the transaction price for a contract based on the total consideration we expect to receive in exchange for the transferred goods or services. The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognizes revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. The Company’s contracts with customers are generally comprised of purchase orders for the sale of the point of care instrument, consumable products, and warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The warranties are also a separate performance obligation, whereby revenue is recognized over time. At times the Company receives consideration prior to when the performance obligation is completed, giving rise to a contract liability. Sales are recorded net of sales tax. Sales tax is charged on sales to end users and remitted to the appropriate state authority. Accounts receivable are recorded at net realizable value and have payment terms of 30 days. The Company recorded an allowance for doubtful accounts for $34,000, which is recorded net in trade receivables. The Diagnostics segment reported $125,361 in revenue from consumables. The Therapeutics segment reported $1,792,865 in revenue from instruments, $2,072,582 from trodes, $28,959, from warranties and services, and $113,356 from other revenues. Cost of revenue Cost of goods sold consists of materials, and shipping costs incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of goods sold. Comparative figures Certain prior year amounts have been reclassified to conform to the current year presentation. The change in presentation had no effect on the reported results of operations. Adjustments have been made to the consolidated balance sheets, consolidated statements of loss and comprehensive loss, and the consolidated statements of cash flows for year ended December 31, 2020. These changes in classification do not affect previously reported cash flows from operating activities in the consolidated statements of cash flows. Basis of measurement The consolidated financial statements have been prepared on the historical cost basis except as otherwise noted. Functional and reporting currencies The functional currency, as determined by management, for our subsidiaries in the United States, Switzerland, and Canada is U.S. dollars, which is also our reporting currency. The functional currency, as determined by management, for our Japanese subsidiary is Japanese Yen. Japanese Yen are translated for financial reporting purposes with translation gains and losses recorded as a component of other comprehensive income or loss. In respect of transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are remeasured at the period end rates. Revenue and expenses are measured at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these transactions are recognized in the consolidated statements of operations and comprehensive loss. Cash and cash equivalents The Company considers all highly liquid securities with an original maturity of three months or less to be cash equivalents. Property and equipment Depreciation is recognized so as to write off the cost less their residual values over their useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in profit or loss. TRUFORMA instruments utilized in the Customer Appreciation Program, ("CAP") are reclassified from inventory and categorized as property and equipment, which is depreciated over the estimated useful life. Estimated useful lives for the principal asset categories are as follows: Office equipment 3 years Machinery and equipment 5-10 years Furniture and equipment 5-7 years Laboratory equipment 5-7 years Leasehold improvements Over shorter of estimated useful life and lease term Impairment of long-lived assets Long-lived assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the sum of estimated undiscounted future cash flows associated with the asset or group of assets is less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Research and development Research and development costs related to continued research and development programs are expensed as incurred. Share issue costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock. Stock-based compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option using the graded vesting method. The provisions of the Company’s stock-based compensation plans do not require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options is excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during fiscal 2021 and 2020 were not included in the computation of diluted EPS because the Company has incurred a loss for the years ended December 31, 2021 and 2020 and the effect would be anti-dilutive. Business combinations We account for business combinations in accordance with ASC 805, Business Combinations, if the acquired assets assumed and liabilities incurred constitute a business. We consider acquired companies to constitute a business if the acquired net assets and processes have the ability to create outputs in the form of revenue. For acquired companies constituting a business, we recognize the identifiable assets acquired and liabilities assumed at their acquisition-date fair values and recognize any excess of total consideration paid over the fair value of the identifiable net assets as goodwill. Comprehensive loss The Company follows ASC topic 220. This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders’ equity. The Company has recorded a currency translation adjustment associated with its Japanese subsidiary. Intangible assets Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives and amortization methods are reviewed at the end of each year, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses. Computer software and website 3 years Trademarks 15 years Tradename 19 years Customer relationships 11 years Developed technology 15 years Fair value measurement Under ASC topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. There are three levels to the hierarchy based on the reliability of inputs, as follows: · Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. · Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active. · Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Income taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, on a tax jurisdictional basis. The Company files income tax returns in Canada and the province of Alberta and its subsidiaries file income tax returns in the United States and various states, including in Michigan where the Company's headquarters are located. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized. The Company assesses the likelihood of the financial statement effect of an uncertain tax position that should be recognized when it is more likely than not that the position will be sustained upon examination by a taxing authority based on the technical merits of the tax position, circumstances, and information available as of the reporting date. The Company is subject to examination by taxing authorities in jurisdictions such as the United States and Canada. The Company recognizes tax-related interest and penalties, if any, as a component separate from income tax expense. Segment reporting The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company's reportable segments in 2021 consist of Diagnostics and Therapeutics. In the prior year, the Company reported as one segment. The addition of the Therapeutics segment is the result of the acquisition of PulseVet, described in Note 5. The accounting policies of the two segments are the same as those described in this Note 3. Recently adopted accounting pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for income Taxes, which is intended to simply various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in ASC 740 and also clarify and amend existing guidance to improve consistent application. This ASU is effect for the Company beginning on January 1, 2021. We adopted this pronouncement as of January 1, 2021, but this pronouncement has no effect on the income tax benefit.

Note 4 - Critical accounting ju

Note 4 - Critical accounting judgments and key sources of estimation uncertainty	12 Months Ended
	Dec. 31, 2021
Note 4 - Critical accounting judgments and key sources of estimation uncertainty
4. Critical Accounting Judgments and Key Sources of Estimation Uncertainly	4. Critical accounting judgments and key sources of estimation uncertainty The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. Critical areas of estimation and judgements in applying accounting policies include the following: Intangible Assets and Business Combinations Assets acquired and the liabilities assumed as part of a business combination are recognized at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. The Company considers inputs to value the assets and liabilities by taking into account competitive trends, market comparisons, independent appraisals, and historical data, among other factors, as supplemented by current and anticipated market conditions. The valuation inputs in these analyses are based on market participant assumptions. The Company may refine these estimates and record adjustments to an asset or liability with the offset to goodwill during the measurement period, which may be up to one year from the acquisition date. Upon the conclusion of the measurement period or final determination of the values of the assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded in the Company’s Consolidated Statements of Income. Inventory Reserves Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Revenue recognition and liabilities due to customers The nature of the Company’s business gives rise to variable consideration, including discounts and applicator (“trode”) returns. Credits are issued for unused shocks on returned trodes, which can be used toward the purchase of replacement trodes. Discounts and the estimated unused shock credits decrease the transaction price, which reduces revenue. Variable consideration related to unused shock credits is estimated using the expected value method, which estimates the amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration are estimated based upon historical experience and known trends. These estimated credits are non-refundable and may only be used towards the purchase of future trode refurbishments. This practice encourages refurbishment purchase prior to complete utilization of the previous trode, so the customer will always have a trode at hand with ample capacity to perform treatments.

Note 5 - Business Combination

Note 5 - Business Combination	12 Months Ended
	Dec. 31, 2021
Note 5 - Business Combination
5. Business Combination	5. Business Combination Acquisition of PulseVet On October 1, 2021, Zomedica Inc., a wholly-owned subsidiary of Zomedica Corp. (the “Company”), entered into a Stock Purchase Agreement with Branford PVT Mid-Hold, LLC pursuant to which Zomedica Inc. acquired 100% of the capital stock of Branford PVT Acquiror, Inc., a Delaware corporation (“BPA”). BPA is a holding company whose direct and indirect wholly-owned subsidiaries include Pulse Veterinary Technologies, LLC (“PulseVet”), which, together with its consolidated subsidiaries, is a leading provider of non-invasive shock wave therapy treatment devices to the veterinary industry (the “Acquisition”). The purchase price for the Acquisition was $71,929,250 in cash. As a result of total consideration exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $43,287,765 was recorded in connection with this acquisition, none of which will be deductible for U.S tax purposes. The goodwill largely results from our ability to market and sell the PulseVet Technology through our established customer base. The Consolidated Statement of Income and Comprehensive income includes $2,350,853 in acquisition-related costs, which are reflected in selling, general and administrative expenses. The Company's 2021 consolidated operating results include revenues of $4,007,762 and net income of $453,697 since the date of acquisition. These results, which are included in the Therapeutics segment include $689,860 of amortization of specific identifiable assets recorded in the opening balance sheet, including developed technology, customer relationships and trade name. The following table summarizes the preliminary acquisition date fair values of the assets acquired and liabilities assumed and subsequent initial period adjustments: Initial allocation of consideration Measurement period adjustments Updated allocation Cash and cash equivalents $ 526,439 $ 3,392 $ 529,831 Inventory 840,159 31,341 871,500 Prepaid expenses and deposits 365,308 - 365,308 Trade receivables 268,342 - 268,342 Other receivables - 150,000 150,000 Property and equipment 124,904 - 124,904 Intangible Assets (estimated useful life) - - - Developed technology (15 years) 8,650,000 - 8,650,000 Trade name (19 years) 2,350,000 - 2,350,000 Customer relationships (11 years) 22,650,000 - 22,650,000 Other Assets 68,882 265,000 333,882 Total assets acquired 35,844,034 449,733 36,293,767 Accounts payable and accrued liabilities 1,113,175 (542,439 ) 570,736 Income tax payable 43,700 - 43,700 Deferred revenue 60,675 - 60,675 Liability for contracts with customers 331,713 - 331,713 Deferred tax liabilities 7,137,789 (900,000) 6,237,789 Other non current liabilities 142,669 265,000 407,669 Total liabilities assumed 8,829,721 (1,177,439 ) 7,652,282 Net assets acquired, excluding goodwill 27,014,313 1,627,172 28,641,485 Goodwill 44,914,937 (1,627,172 ) 43,287,765 Net assets acquired $ 71,929,250 $ - $ 71,929,250 Pro Forma Results (unaudited) The following table provides unaudited pro forma financial information, prepared in accordance with Topic 805, for the years ended December 31, 2021, and 2020, as if PulseVet had been acquired as of January 1, 2020, Proforma results do not include the effect of any synergies anticipated to be achieved from the acquisition, and accordingly, are not necessarily indicative of the results that would have occurred if the acquisition had occurred on the date indicated or that may result in the future. Year Ended December 31, 2021 2020 Net revenue $ 12,669,574 $ 7,077,966 Net losses (18,424,357 ) (17,335,497 ) The pro forma amounts have been calculated by including the results of PulseVet, and adjusting the combined results to give effect to the following, as if the acquisitions had been consummated on January 1, 2020, together with the consequential tax effects thereon: Year ended December 31, 2021 2020 Adjustments to net revenues PulseVet preacquistion revenues $ 8,536,451 $ 7,077,966 Adjustments to net income PulseVet preacquistion net losses (41,187 ) (423,713 )

Note 6 - Inventory

Note 6 - Inventory	12 Months Ended
	Dec. 31, 2021
Note 6 - Inventory
6. Inventory	6 . Inventory The detail of inventory is as follows: Diagnostics Therapeutics Consolidated Raw Materials $ - $ 890,446 $ 890,446 Finished Goods - 139,996 139,996 Purchased Inventory 1,848,495 - 1,848,495 Total 1,848,495 1,030,442 2,878,937 - Reserves (8,855 ) (22,097 ) (30,952 ) Inventory, Net $ 1,839,640 $ 1,008,345 $ 2,847,985

Note 7 - Prepaid expenses, depo

Note 7 - Prepaid expenses, deposits and deferred financing costs	12 Months Ended
	Dec. 31, 2021
Note 7 - Prepaid expenses, deposits and deferred financing costs
7. Prepaid expenses, deposits and deferred financing costs	7. Prepaid expenses, deposits, and deferred financing costs December 31, December 31, 2021 2020 Deposits $ 1,339,862 $ 1,455,119 Prepaid marketing 83,347 26,330 Prepaid insurance 598,668 184,154 Other 214,043 76,135 Total $ 2,235,920 $ 1,741,738

Note 8 - Property and Equipment

Note 8 - Property and Equipment	12 Months Ended
	Dec. 31, 2021
Note 8 - Property and Equipment
8. Property and equipment	8. Property and equipment December 31, December 31, 2021 2020 Machinery and office equipment $ 1,466,778 $ 364,165 Furniture and equipment 110,244 121,281 Laboratory equipment 225,330 234,087 Leasehold improvements 287,451 571,460 2,089,803 1,290,993 Accumulated depreciation and amortization 884,257 707,986 Net property and equipment $ 1,205,546 $ 583,007 Depreciation expense for the year ended December 31, 2021 and 2020 was $265,496 and $305,914.

Note 9 - Intangible Assets

Note 9 - Intangible Assets	12 Months Ended
	Dec. 31, 2021
Note 9 - Intangible Assets
9. Intangible Assets	9. Intangible Assets December 31, December 31, 2021 2020 Computer software $ 28,097 $ 22,882 Trademarks 16,235 16,236 Website 889,456 513,680 Tradename 2,350,000 - Customer Relationships 22,650,000 - Technology 8,650,000 - 34,583,788 552,798 Accumulated amortization 1,064,228 190,135 Net intangibles $ 33,519,560 $ 362,663 The estimated future amortization of intangible assets is as follows: 2022 $ 2,946,754 2023 2,772,784 2024 2,767,546 2025 2,760,517 2026 and beyond 22,271,959 Total $ 33,519,560 Amortization expense for the year ended December 31, 2021 and 2020 was $874,093 and $224,106.

Note 10 - Leases

Note 10 - Leases	12 Months Ended
	Dec. 31, 2021
Note 10 - Leases
10. Leases	10. Leases On February 1, 2020, the Company cancelled its existing lease with Wickfield Phoenix LLC. and entered a new lease. The new lease period was for 60 months, commencing on February 1, 2020, and ending on January 31, 2025, with a monthly rent payment of $32,452 escalating to $36,525 over the lease period. Upon cancellation of the previous existing lease, the Company received a refund of prepaid rent in the amount of $1,002,113. The carrying value of the right of use asset was $1,061,210 upon cancellation. The Company recorded a loss on right-of-use asset of $59,097 during the year ended December 31, 2020 in the consolidated statements of comprehensive loss. On February 1, 2020, the Company recorded a right-of-use asset and a corresponding lease liability in the amount of $1,553,611 using the Company’s incremental borrowing rate of 12%. On February 1, 2021, the Company downsized its office space and modified its existing lease with Wickfield Phoenix LLC. The new lease period was for 48 months, commencing on February 1, 2021, and ending on January 31, 2025, with a monthly rent payment of $12,039 for the first two months and escalating to $30,911 over the lease period. The carrying value of the right of use asset was $1,258,263 upon modification. The Company recorded a gain on right-of-use asset of $731 during the year ended December 31, 2021 in the consolidated statements of comprehensive loss. On February 1, 2021, the Company recorded a right-of-use asset and a corresponding lease liability in the amount of $1,281,609 using the Company’s incremental borrowing rate of 3.95%. On September 15, 2021, the Company entered into an additional lease with Wickfield Phoenix LLC for warehousing space. The new lease period is for 41 months, commencing on September 15, 2021, and ending on January 31, 2025, with a monthly rent payment of $4,580 for the first month and escalating to $10,009 over the lease period. The Company recorded a right-of-use asset and corresponding lease liability for $365,840 using the Company's incremental borrowing rate of 3.95%. During year ended December 31, 2021, the Company recognized $411,315 in rent expense, with $94,544 recorded in research and development expenses, and $315,771 recorded in general and administrative expense, in the consolidated statements of comprehensive loss. During the year ended December 31, 2020, the Company recognized $379,041 in rent expense with $83,425 recorded in research and development expenses and $295,616 recorded in general and administrative expense in the consolidated statements of comprehensive loss. During the year ended December 31, 2020, the Company also recorded $4,331 in rent expense related to month-to-month leases with the entirety in general and administrative expense in the consolidated statements of operations and comprehensive loss. 2021 2020 Right-of-use asset Cost Aggregate lease commitments $ 1,778,798 $ 2,067,505 Less: impact of present value (154,695 ) (513,894 ) Balance 1,624,103 1,553,611 Reduction in right-of-use asset Straight line amortization 346,457 379,043 Interest (42,164 ) (144,148 ) Balance 304,293 234,895 Net book value $ 1,319,810 $ 1,318,716 Lease liabilities Additions $ 1,647,449 $ 1,553,611 Payments (310,726 ) (356,972 ) Interest 42,163 144,147 Total lease liabilities at December 31, 2021 1,378,886 1,340,786 Current portion of lease liabilities 414,695 252,788 Long term portion of lease liabilities 964,191 1,087,998 Total lease liabilities at December 31, 2021 $ 1,378,886 $ 1,340,786 Total remaining undiscounted lease liabilities related to the above lease are as follows: 2022 $ 461,726 2023 475,579 2024 489,845 2025 40,920 Total $ 1,468,070

Note 11 - Loan Arrangements

Note 11 - Loan Arrangements	12 Months Ended
	Dec. 31, 2021
Note 7 - Prepaid expenses, deposits and deferred financing costs
11. Loan Arrangements	11. Loan Arrangements The Coronavirus Aid, Relief, and Economic Security Act, or (“CARES”) Act, was signed into law on March 27, 2020, and provides over $2.0 trillion in emergency economic relief to individuals and businesses impacted by the COVID-19 pandemic. The CARES Act authorized the Small Business Administration to temporarily guarantee loans under a new loan program called the Paycheck Protection Program (the “Program”). The Program provides for 100% federally guaranteed loans to small businesses to allow employers to keep workers employed and maintain payroll during the pandemic and economic downturn. In April of 2020, the Company received $527,360 under the program. The receipt was reported as a current liability and accounted for as a loan. The Company was granted forgiveness on June 13, 2021 and recorded a gain on the extinguishment of debt for $533,414, inclusive of $6,054 in accrued interest.

Note 12 - Preferred stock

Note 12 - Preferred stock	12 Months Ended
	Dec. 31, 2021
Note 12 - Preferred stock
12. Preferred stock	12. Preferred stock The Company is authorized to issue up to 20 shares of our Series 1 Preferred Shares, all without par value, and each having a stated value of $1,000,000. The Series 1 Preferred Shares do not have voting rights except to the extent required by applicable law and are not convertible into the Company’s common shares. Holders of the Series 1 Preferred Shares will not be entitled to dividends but, in lieu thereof, will receive Net Sales Returns (“Net Sales Returns” is defined as annual payments equal to 9 percent of net sales) until such time as the holders have received total Net Sales Returns equal to 9 times the aggregate stated value of the outstanding Series 1 Preferred Shares. The Company will have the right to redeem the outstanding Series 1 Preferred Shares at any time at a redemption price equal to 9 times the aggregate stated value of the Series 1 Preferred Shares outstanding less the aggregate amount of the Net Sales Returns paid (the “Redemption Amount”). Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series 1 Preferred Shares will be entitled to a liquidation preference equal to the stated value of the Series 1 Preferred Shares less the Net Sales Returns paid on the Series 1 Preferred Shares. In the event of a fundamental transaction (defined to include an amalgamation, merger or other business combination transaction involving our company in which our shareholders do not have the right to cast more than 50% of the votes that may be cast for the election of directors, or a sale, lease or other disposition of the properties and/or assets of our company as an entirety or substantially as an entirety to a third party), the holders of the Series 1 Preferred Shares will be entitled to receive consideration for their Series 1 Preferred Shares equal to a multiple of the stated value of the Series 1 Preferred Shares ranging from 5.0 to 9.0 depending on the timing of the fundamental transaction, subject to a cap equal to the redemption amount. Due to financings completed during the year ended December 31, 2020, the Company has reclassified the preferred stock from equity into mezzanine equity because a fundamental transaction would not be under the sole control of management and the Company. Issued and outstanding preferred stock: Number of Preferred preferred stock stock amount Balance at December 31, 2019 12 $ 11,961,397 Balance at December 31, 2020 12 $ 11,961,397 Stock exchanged (12 ) $ (11,961,397 ) Balance at December 31, 2021 - $ - On March 7, 2021, the Company exchanged the issued and outstanding shares of its Series 1 Preferred Shares for 24,719,101 of common shares valued at $44,000,000. The difference between the carrying value of the preferred shares and the fair value of the common shares exchanged of $32,038,603 was charged to accumulated deficit.

Note 13 - Common Stock

Note 13 - Common Stock	12 Months Ended
	Dec. 31, 2021
Note 4 - Critical accounting judgments and key sources of estimation uncertainty
13. Common Stock	13. Common stock i) On February 14, 2020, the Company completed a registered direct offering (“RDO”) of its common shares and a simultaneous private placement of its warrants (“Series A Warrants”) in a fixed combination of one common share and a Series A Warrant to purchase one common share, resulting in the sale of 20,833,334 common shares and Series A Warrants to purchase 20,833,334 common shares at a combined offering price of $0.12 per share and related Series A Warrant. Each Series A Warrant has an exercise price of $0.20 per share, is exercisable six months after issuance and has a term of 5- and one-half years. The Company also issued warrants to the placement agents to purchase 1,041,667 common shares at an exercise price of $0.15 per share (“Series A Placement Agent Warrants”), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 20,833,334 common shares, 20,833,334 Series A Warrants, and an additional 1,041,667 Series A Placement Agent Warrants. The Company raised $2,500,000 in gross proceeds as part of the RDO. The Company recorded $1,705,655 as the value of common shares under common stock and $794,345 as the value of Series A Warrants (as disclosed in Note 13) under additional paid-in-capital in the consolidated statements of shareholders’ equity using the relative fair value approach. The direct cash costs related to the issuance of the common shares and warrants issued in February 2020 were $348,220. These direct costs were recorded as an offset against the statement of shareholders’ equity with $238,217 being recorded under capital stock and $110,003 being recorded under additional paid-in-capital. The Company also recorded the value of the Series A Placement Agent Warrants in the amount of $52,496 as an offset against the statement of shareholders’ equity with $35,816 being recorded under capital stock and $16,680 being recorded under additional paid-in-capital. (ii) On April 9, 2020 the Company completed a confidentially marketed public offering (“CMPO”) of its common shares and warrants (“Series B Warrants”) of 33,333,334 common shares and warrants to purchase up to 16,666,667 common shares. The securities were sold in a fixed combination of one common share and 0.5 of a Series B Warrant at a combined offering price of $0.12 per share and accompanying warrant. Each whole warrant is exercisable immediately for one common share after issuance, at an exercise price of $0.15 per share and has a term of 5 years. The Company also issued warrants to the placement agents to purchase 1,666,667 common shares at an exercise price of $0.15 per share (“Series B Placement Agent Warrants”), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 33,333,334 common shares, 16,666,667 Series B Warrants, and an additional 1,666,667 Series B Placement Agent Warrants. The Company raised $4,000,000 in gross proceeds in the CMPO. The Company recorded $2,942,248 as the value of common shares under common stock and $1,057,752 as the value of Series B Warrants (as disclosed in Note 13) under additional paid-in-capital in the consolidated statements of shareholders’ equity using the relative fair value approach. The direct cash costs related to the issuance of the common shares and warrants issued in April were $582,977. These direct costs were recorded as an offset against the statement of shareholders’ equity with $428,283 being recorded under capital stock and $154,694 being recorded under additional paid-in-capital. The Company also recorded the value of the Series B Placement Agent Warrants in the amount of $161,714 as an offset against the statement of shareholders’ equity, with $118,951 being recorded under capital stock and $42,763 being recorded under additional paid-in-capital. (iii) On May 29, 2020 the Company completed a public offering of its common shares or common share equivalents (“Series C Pre-Funded Warrants”), and warrants (“Series C Warrants”) in a fixed combination of one common share or Series C Pre-Funded Warrant, and a Series C Warrant to purchase one common share, resulting in the sale of 121,163,333 common shares, 12,170,000 Series C Pre-Funded Warrants, and Series C Warrants to purchase 133,333,333 common shares at a combined offering price of $0.15 per share for the common shares and related Series C Warrant, or a combined offering price of $0.1499 per Series C Pre-Funded Warrant and related Series C Warrant. Each Series C Pre-Funded Warrant has an exercise price of $0.0001 per share, is exercisable immediately after issuance, is exercisable only on a cashless exercise basis, and will not expire prior to exercise. Each Series C Warrant has an exercise price of $0.15 per share, is exercisable immediately after issuance and has a term of 2 years. The Company raised $19,998,783 in gross proceeds as part of the public offering. The Company recorded $11,336,422 as the value of common shares under common stock, $1,080,289 as the value of the Series C Pre-Funded Warrants and $7,582,072 as the value of Series C Warrants (as disclosed in Note 13) under additional paid-in-capital in the consolidated statements of shareholders’ equity using the relative fair value approach. The direct cash costs related to the issuance of the common shares, Series C Pre-Funded Warrants and Series C Warrants issued in May 2020 were $1,908,202. These direct costs were recorded as an offset against the statement of shareholders’ equity with $1,088,876 being recorded under capital stock and $819,327 being recorded under additional paid-in-capital. (iv) On July 7, 2020 the Company completed a public offering of its common shares or common share equivalents (“Series D Pre-Funded Warrants”), and warrants (“Series D Warrants”) in a fixed combination of one common share or Series D Pre-Funded warrant, and a Series D Warrant to purchase one common share, resulting in the sale of 162,500,000 common shares, 25,000,000 Series D Pre-Funded Warrants, and Series D Warrants to purchase 187,500,000 common shares at a combined offering price of $0.16 per share for the common shares and related Series D Warrant, or a combined offering price of $0.1599 per Series D Pre-Funded Warrant and related Series D Warrant. Each Series D Pre-Funded Warrant has an exercise price of $0.0001 per share, is exercisable immediately after issuance, is exercisable only on a cashless exercise basis, and will not expire prior to exercise. Each Series D Warrant has an exercise price of $0.16 per share, is exercisable immediately after issuance, and has a term of 2 years. The Company raised $29,997,500 in gross proceeds as part of the public offering. The Company recorded $16,290,941 as the value of common shares under common stock, $2,329,983 as the value of the Series D Pre-Funded Warrants and $11,376,575 as the value of the Series D Warrants (as disclosed in Note 13) under additional paid-in-capital in the consolidated statements of shareholders’ equity using the relative fair value approach. The direct cash costs related to the issuance of the common shares, Series D Pre-Funded Warrants and Series D Warrants issued in July 2020 were $2,268,215. These direct costs were recorded as an offset against the statement of shareholders’ equity with $1,224,218 being recorded under capital stock and $1,043,997 being recorded under additional paid-in-capital. (v) All Series C Pre-Funded Warrants were exercised in June 2020. The cashless exercise option resulted in the issuance of 12,162,492 shares. (vi) All Series D Pre-Funded Warrants were exercised in July 2020. The cashless exercise, option resulted in the issuance of 24,984,492 shares. (vii) On February 8, 2021, the Company completed a sale of 91,315,790 common shares at an offering price of $1.90 per share. The Company also granted the underwriter a 30-day option to purchase up to 13,697,368 additional common shares at the public offering price. The Company raised $199,525,000 in gross proceeds as part of the offering. The Company recorded $199,525,000 as the value of common shares under common shares. The direct cash costs related to the issuance of the common shares and warrants issued in February 2021 were $14,280,914. These direct costs were recorded as an offset against the statement of shareholders’ equity with the entirety recorded under common shares.

Note 14 - Stock-based compensat

Note 14 - Stock-based compensation	12 Months Ended
	Dec. 31, 2021
Note 14 - Stock-based compensation
14. Stock-based compensation	14. Stock-based compensation During the year ended December 31, 2021, the Company issued 24,750,000 stock options, each option entitling the holder to purchase one common share of the Company. The options vest over a period of four years and have an expiration period of ten years. During the year ended December 31, 2021, 7,022,776 options were exercised, and the Company received $1,768,461 in cash receipts and reclassified $1,051,225 of additional paid in capital to common stock due to the exercise of stock options. During the year ended December 31, 2020, the Company issued 35,471,000 stock options, each option entitling the holder to purchase one common share of the Company. The options vest over a period of four years and have an expiration period of five years. During the year ended December 31, 2020, no options were exercised. For the years ended December 31, 2021, and December 2020, the Company recorded $7,092,031 and $1,656,184 of stock-based compensation. The continuity of stock options are as follows: Number of Weighted Avg options Exercise Price Balance at December 31, 2020 39,604,515 $ 0.36 Stock options granted 24,750,000 0.72 Stock options exercised 7,022,776 0.25 Unvested stock options forfeited 2,580,000 0.54 Vested stock options expired 4,034,015 1.52 Balance at December 31, 2021 50,717,724 $ 0.45 Vested at December 31, 2021 18,347,474 $ 0.28 As of December 31, 2021, details of the issued and outstanding stock options are as follows: Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) March 14, 2020 0.19 3,018,557 2,025,807 992,750 3.20 July 9, 2020 0.18 175,000 87,500 87,500 3.52 August 25, 2020 0.13 20,000 - 20,000 3.65 September 29, 2020 0.11 225,000 225,000 - 3.75 October 1, 2020 0.11 266,667 116,667 150,000 3.75 October 20, 2020 0.09 20,000 10,000 10,000 3.81 December 31, 2020 0.23 23,442,500 14,682,500 8,760,000 9.00 February 26, 2021 1.87 600,000 150,000 450,000 9.16 March 1, 2021 2.06 200,000 50,000 150,000 9.17 March 8, 2021 1.88 200,000 50,000 150,000 9.19 March 15, 2021 2.49 200,000 50,000 150,000 9.21 May 12, 2021 0.78 3,600,000 850,000 2,750,000 9.36 May 14, 2021 0.75 3,200,000 50,000 3,150,000 9.37 August 11, 2021 0.57 1,300,000 - 1,300,000 9.61 August 18, 2021 0.50 200,000 - 200,000 9.63 August 23, 2021 0.50 100,000 - 100,000 9.65 September 13, 2021 0.57 800,000 - 800,000 9.70 September 27, 2021 0.54 500,000 - 500,000 9.74 October 1, 2021 0.58 12,650,000 - 12,650,000 9.75 Balance at December 31, 2021 50,717,724 18,347,474 32,370,250 The Company calculates volatility of stock-based compensation using the historical price of the Company’s stock. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. The fair value of options granted during the year ended December 31, 2021 was estimated using the Black-Scholes option pricing model to determine the fair value of options granted using the following assumptions: February 26, 2021 March 1, 2021 March 8, 2021 Volatility 117 % 117 % 117 % Risk-free interest rate 0.95 % 0.92 % 1.07 % Expected life 10 years 10 years 10 years Dividend yield 0 % 0 % 0 % Common share price $ 1.87 $ 2.06 $ 1.88 Strike price $ 1.87 $ 2.06 $ 1.88 Forfeiture rate zero zero zero May 12, 2021 August 11, 2021 August 23, 2021 Volatility 118 % 116 % 116 % Risk-free interest rate 1.11 % 0.96 % 0.92 % Expected life 6.21 - 6.22 Years 6.18 - 6.25 6.25 Dividend yield 0 % 0 % 0 % Common share price $ 0.78 $ 0.56 $ 0.50 Strike price $ 0.78 $ 0.57 $ 0.50 Forfeiture rate zero zero zero September 27, 2021 October 1, 2021 Volatility 116 % 116 % Risk-free interest rate 1.14 % 1.10 % Expected life 6.25 6.25 Dividend yield 0 % 0 % Common share price $ 0.54 $ 0.57 Strike price $ 0.54 $ 0.58 Forfeiture rate zero zero

Note 15 - Warrants

Note 15 - Warrants	12 Months Ended
	Dec. 31, 2021
Note 15 - Warrants
15. Warrants	15. Warrants In connection with the February 14, 2020 RDO, the Company issued 20,833,334 five and one half-year Series A Warrants to purchase one common share at an exercise price of $0.20. The Company also issued 1,041,667 Series A Placement Agent Warrants to purchase one common share at an exercise price of $0.15 per share. In connection with the April 9, 2020 CMPO, the Company issued 16,666,667 five-year Series B Warrants to purchase one common share at an exercise price of $0.15. The Company also issued 1,666,667 Placement Agent Warrants to purchase one common at an exercise price of $0.15 per share. In connection with the May 29, 2020 public offering, the Company issued 133,333,333 two-year Series C Warrants to purchase one common share at an exercise price of $0.15. The Company also issued 12,170,000 Series C Pre-Funded Warrants to purchase common shares at an exercise price of $0.0001 on a cashless exercise basis. As of December 31, 2020, the Series C Pre-Funded Warrants have all been exercised. In connection with the July 7, 2020 public offering, the Company issued 187,500,000 two-year Series D Warrants to purchase one common share at an exercise price of $0.16. The Company also issued 25,000,000 Series D Pre-Funded Warrants to purchase common shares at an exercise price of $0.0001 on a cashless exercise basis. As of December 31, 2020, the Series D Pre-Funded Warrants have all been exercised. As of December 31, 2021, details of the outstanding warrants were as follows: Original Issue date Exercise Price Warrants Outstanding Weighted Average Remaining Life February 14, 2020 0.15 197,917 3.12 April 9, 2020 0.15 363,501 3.27 May 29, 2020 0.15 120,000 0.41 July 7, 2020 0.16 231,000 0.52 Balance at December 31, 2021 912,418 Cumulative warrant exercised as of December 31, 2021 were as follows: Warrants Warrant series exercised Amount Series A 21,677,084 $ 4,293,229 Series B 17,969,833 2,695,475 Series C 133,213,333 19,982,000 Series D 187,269,000 29,963,040 Subtotal 360,129,250 56,933,744 Common stock subscribed - (459,600 ) Total 360,129,250 $ 56,474,144

Note 16 - Income taxes

Note 16 - Income taxes	12 Months Ended
	Dec. 31, 2021
Note 16 - Income taxes
16. Income taxes	16. Income taxes The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 23% (2020- 28%) to the effective tax rate is as follows: December 31, 2021 December 31, 2020 Loss before income taxes $ (20,716,224 ) $ (16,911,784 ) Expected income tax benefit 4,764,732 4,058,828 Difference in foreign rates (180,419 ) 74,847 Tax rate changes and other adjustments (48,230 ) (1,540,539 ) Stock based compensation and nondeductible expenses (1,394,102 ) (407,689 ) Foreign accrual property income (15,870 ) (210,605 ) Prior period adjustment (161,752 ) (32,518 ) Share issuance costs recorded in equity 3,284,610 1,282,179 Section 382 derecognition (4,343,851 ) - Change in valuation allowance 427,936 (3,224,503 ) Total Income tax benefit $ 2,333,054 $ - The following table summarizes the components of deferred tax: 2021 2020 Deferred tax assets Intangible assets - licenses $ 4,236,137 $ 4,236,169 Share issuance costs 3,425,321 1,148,179 Reserves 180,700 28,784 Non-capital loss carried forward - Canada 8,386,587 6,182,002 Net operating losses carried forward - US 2,591,577 5,091,162 Investment tax credits 30,000 27,328 Operating leases 4,022 345,937 Other - 466 Total deferred tax assets 18,854,344 17,060,027 Deferred tax liabilities Property and equipment (138,918 ) (94,218 ) Right-of-use asset - (340,242 ) Intangibles (6,078,850 ) - Other (148,257) - Total deferred tax liabilities (6,366,025 ) (434,460 ) Valuation allowance 16,197,631 16,625,567 Net deferred tax liability $ (3,709,312 ) $ - Certain deferred tax assets have not been recognized, as it is not more likely than not they will be realized. Consequently, a valuation allowance has been applied against these net deferred tax assets. The Canadian non-capital loss carry forwards expire as noted in the table below. 2036 $ 3,763,071 2037 $ 4,278,944 2038 $ 5,416,916 2039 $ 6,773,728 2040 $ 7,417,578 2041 $ 9,629,482 Total $ 37,279,719 The Company’s US non-operating income tax losses expire as follows: 2035 $ 856,301 2036 $ 1,484,636 2037 $ 3,831,764 indefinitely (subject to 80% limitation) $ 22,005,181 Derecognized under Section 382 $ (20,975,994 ) Total $ 7,201,888 As of December 31, 2021, we had net operating loss carryforwards for U.S. federal and state income tax purposes of approximately $28.1 million and noncapital loss carryforwards for Canada of approximately $37.3 million, which will begin to expire in fiscal year 2035. We have evaluated the factors bearing upon the realizability of our deferred tax assets, which are comprised principally of net operating loss carryforwards and noncapital loss carryforwards. We concluded that, due to the limitations under Section 382, our U.S. federal and state income tax net operating loss carryfowards, as well as R&D credit carryfowards, for the periods prior to February 11, 2021 have been limited to zero. We therefore have derecognized $21.0 million of this asset and reduced the carryforward of these amounts to $7.2 million. Zomedica entered into a Stock Purchase Agreement on October 1, 2021, to acquire 100% of the equity of Branford PVT Mid-Hold, LLC, of which PulseVet is a wholly owned subsidiary. This transaction was treated as a non-taxable stock acquisition for U.S. federal income tax purposes. In connection with the acquisition, deferred tax liabilities of $6.2 million, were recorded related to a step up of book basis in definite-lived intangible assets recorded in purchase accounting as described in Note 5, Business Combination. In connection with the PulseVet transaction, it was assessed that an uncertain tax position exists related to withholding taxes on royalties for approximately $265,000. An uncertain tax liability and an indemnification asset were recorded. It is the Company's policy to record interest within income tax expense and penalties in selling, general, and administrative costs outside of income tax expense. Tax years subject to examination for US federal and state jurisdictions are generally years from 2018 and forward. Tax years subject to examination in Canada are from years 2017 forward. As a result of the acquisition, the deferred tax liability related to the transaction created a source of future taxable income in the US. The Company is in an overall net deferred tax liability position for the year ended December 31, 2021. Management has assessed that the future taxable income resulting from the deferred tax liability position will result in utilization of the company's US federal and state net operating loss carryforwards and has therefore released the valuation allowance for U.S. tax assets. Due to the uncertainty of realizing any tax benefits as of December 31, 2021 due to historical losses, a full valuation allowance remains necessary to fully offset our Canadian deferred tax assets.

Note 17 - Commitments and conti

Note 17 - Commitments and contingencies	12 Months Ended
	Dec. 31, 2021
Note 17 - Commitments and contingencies
17. Commitments and contingencies	17. Commitments and contingencies On September 20, 2021, Heska Corporation (“Heska”), Qorvo US, Inc. (“Qorvo US”), Qorvo Biotechnologies, LLC (“Qorvo Biotech” and, together with Qorvo US, “Qorvo”) and our company (collectively with Qorvo, the “Defendants”) entered into a settlement agreement pursuant to which the litigation previously commenced by Heska against the Defendants in the United States District Court for the Middle District of North Carolina, Case 1:19-cv-01108-LCB-JLW, was dismissed with prejudice. Pursuant to the settlement agreement, the parties also provided mutual releases of any and all claims related to the subject matter of the litigation. We were not required to make any payment or agree to any covenants restricting the conduct of our business in connection with the settlement. On May 10, 2018, the Company entered into a Development, Commercialization and Exclusive Distribution Agreement. As part of the agreement, the Company is required to make the following future milestone payments: · 1st payment: $3,500,000 in cash payment upon the achievement of future development milestones · 2nd payment: $3,500,000 in equity, determined by dividing the amount due by the volume-weighted average price of the Company’s common stock on the NYSE American exchange over the 10 trading days prior to the achievement of the milestone event. As of December 31, 2021, none of the future development milestones related to the above agreement have been met. The Company has assessed the probability of meeting the above milestones and has determined that an accrual is not necessary as of December 31, 2021, and December 31, 2020. From time to time, the Company may be exposed to claims and legal actions in the normal course of business. As of December 31, 2021, and continuing as of February 25, 2022, the Company is not aware of any pending or threatened material litigation claims against the Company

Note 18 - Segmented information

Note 18 - Segmented information	12 Months Ended
	Dec. 31, 2021
Note 18 - Segmented information
18. Segmented Information	18. Segmented information The Company's operations are comprised of two reportable segments. Although the reportable segments provide similar products, each one is managed separately to better align with the Company’s customers and distribution or development partners. In addition, all of the Company’s long-lived assets are in the United States of America (“US”). Diagnostics Therapeutics Consolidated Net Revenue $ 125,361 $ 4,007,762 $ 4,133,123 Operating (loss) income (22,414,463) 1,046,466 (21,367,997) Net interest income 347,611 3,782 351,393 Other gains 47,929 3,932 51,861 (Loss) income before income taxes $ (21,740,247 ) $ 1,024,023 $ (20,716,224 ) Total assets $ 199,556,729 $ 80,842,564 $ 280,399,293 Depreciation and amortization 425,981 713,608 1,139,589 Capital expenditures $ 523,656 2,293 $ 525,949 December 31, December 31, 2021 2020 Canada $ 170,601,082 $ 53,160,701 US 109,798,211 12,983,333 Total assets $ 280,399,293 $ 66,144,034 Total US property and equipment $ 1,205,546 $ 583,007 Total US right-of-use asset $ 1,319,810 $ 1,318,716

Note 19 - Loss per share

Note 19 - Loss per share	12 Months Ended
	Dec. 31, 2021
Note 19 - Loss per share
19. Loss per share	19. Loss per share For the year ended For the year ended December 31, 2021 December 31, 2020 Numerator Net loss for the year $ (18,383,170 ) $ (16,911,784 ) Charge to retained earnings for preferred share exchange (32,038,603 ) - Denominator 956,533,761 364,444,664 Weighted average shares - basic - - Warrants - - Stock options - - Denominator for diluted loss per share 956,533,761 364,444,664 Loss per share - basic and diluted $ (0.05 ) $ (0.05 ) As of December 31, 2021, and 2020, the Company had stock options outstanding of 50,717,724 and 39,604,515 and warrants outstanding of 912,418 and 202,020,823. These securities could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted loss per share in the periods presented, as their effect would be anti‑dilutive.

Note 20 - Subsequent Events

Note 20 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Note 20 - Subsequent Events
Note 20 - Subsequent Events	20. Subsequent Events The Company has evaluated events and transactions occurring subsequent to the consolidated balance sheet date of December 31, 2021 for items that could potentially be recognized or disclosed in these financial statements. We did not identify any items which would require disclosure in or adjustment to the consolidated financial statements.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Note 3 - Significant Accounting Policies
Estimates and assumptions	In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur, and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.
Inventories	Inventories are stated at the lower of cost or net realizable value. The Company utilizes the specific identification and First in, First out ("FIFO") method to track inventory costs. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles
Intangible Assets	Intangible Assets Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life. Costs related to acquired trademarks, tradename, customer relationships and developed technology have been capitalized and amortized over the estimated useful life.
Revenue recognition	Revenue recognition The Company enters into agreements which may contain multiple promises where customers purchase products, services or a combination thereof. Determining whether products and services are considered distinct performance obligations that should be accounted for separately requires judgment. We determine the transaction price for a contract based on the total consideration we expect to receive in exchange for the transferred goods or services. The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognizes revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. The Company’s contracts with customers are generally comprised of purchase orders for the sale of the point of care instrument, consumable products, and warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The warranties are also a separate performance obligation, whereby revenue is recognized over time. At times the Company receives consideration prior to when the performance obligation is completed, giving rise to a contract liability. Sales are recorded net of sales tax. Sales tax is charged on sales to end users and remitted to the appropriate state authority. Accounts receivable are recorded at net realizable value and have payment terms of 30 days. The Company recorded an allowance for doubtful accounts for $34,000, which is recorded net in trade receivables. The Diagnostics segment reported $125,361 in revenue from consumables. The Therapeutics segment reported $1,792,865 in revenue from instruments, $2,072,582 from trodes, $28,959, from warranties and services, and $113,356 from other revenues.
Cost of revenue	Cost of revenue Cost of goods sold consists of materials, and shipping costs incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of goods sold.
Comparative figures	Comparative figures Certain prior year amounts have been reclassified to conform to the current year presentation. The change in presentation had no effect on the reported results of operations. Adjustments have been made to the consolidated balance sheets, consolidated statements of loss and comprehensive loss, and the consolidated statements of cash flows for year ended December 31, 2020. These changes in classification do not affect previously reported cash flows from operating activities in the consolidated statements of cash flows.
Functional and reporting currencies	Functional and reporting currencies The functional currency, as determined by management, for our subsidiaries in the United States, Switzerland, and Canada is U.S. dollars, which is also our reporting currency. The functional currency, as determined by management, for our Japanese subsidiary is Japanese Yen. Japanese Yen are translated for financial reporting purposes with translation gains and losses recorded as a component of other comprehensive income or loss. In respect of transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are remeasured at the period end rates. Revenue and expenses are measured at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these transactions are recognized in the consolidated statements of operations and comprehensive loss.
Cash and Cash Equivalents	The Company considers all highly liquid securities with an original maturity of three months or less to be cash equivalents.
Property and equipment	Property and equipment are carried at historical cost less accumulated depreciation and any accumulated impairment losses. Property and equipment acquired in a business combination are recorded at fair value as of the date of acquisition. Maintenance and repair expenditures that do not improve or extend the life are expensed in the period incurred. Depreciation is recognized so as to write off the cost less their residual values over their useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in profit or loss. TRUFORMA instruments utilized in the Customer Appreciation Program, ("CAP") are reclassified from inventory and categorized as property and equipment, which is depreciated over the estimated useful life. Estimated useful lives for the principal asset categories are as follows: Office equipment 3 years Machinery and equipment 5-10 years Furniture and equipment 5-7 years Laboratory equipment 5-7 years Leasehold improvements Over shorter of estimated useful life and lease term
Impairment of long-lived assets	Long-lived assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the sum of estimated undiscounted future cash flows associated with the asset or group of assets is less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.
Research and development	Research and development costs related to continued research and development programs are expensed as incurred.
Share issue costs	Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock.
Stock-based compensation	The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option using the graded vesting method. The provisions of the Company’s stock-based compensation plans do not require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Loss per share	Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options is excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during fiscal 2021 and 2020 were not included in the computation of diluted EPS because the Company has incurred a loss for the years ended December 31, 2021 and 2020 and the effect would be anti-dilutive.
Business combinations	We account for business combinations in accordance with ASC 805, Business Combinations, if the acquired assets assumed and liabilities incurred constitute a business. We consider acquired companies to constitute a business if the acquired net assets and processes have the ability to create outputs in the form of revenue. For acquired companies constituting a business, we recognize the identifiable assets acquired and liabilities assumed at their acquisition-date fair values and recognize any excess of total consideration paid over the fair value of the identifiable net assets as goodwill.
Comprehensive loss	The Company follows ASC topic 220. This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders’ equity. The Company has recorded a currency translation adjustment associated with its Japanese subsidiary.
Intangible asset	Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives and amortization methods are reviewed at the end of each year, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses. Computer software and website 3 years Trademarks 15 years Tradename 19 years Customer relationships 11 years Developed technology 15 years
Fair value measurement	Under ASC topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. There are three levels to the hierarchy based on the reliability of inputs, as follows: · Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active. · Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.
Income taxes	Income taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, on a tax jurisdictional basis. The Company files income tax returns in Canada and the province of Alberta and its subsidiaries file income tax returns in the United States and various states, including in Michigan where the Company's headquarters are located. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized. The Company assesses the likelihood of the financial statement effect of an uncertain tax position that should be recognized when it is more likely than not that the position will be sustained upon examination by a taxing authority based on the technical merits of the tax position, circumstances, and information available as of the reporting date. The Company is subject to examination by taxing authorities in jurisdictions such as the United States and Canada. The Company recognizes tax-related interest and penalties, if any, as a component separate from income tax expense.
Segmented reporting	Segment reporting The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company's reportable segments in 2021 consist of Diagnostics and Therapeutics. In the prior year, the Company reported as one segment. The addition of the Therapeutics segment is the result of the acquisition of PulseVet, described in Note 5. The accounting policies of the two segments are the same as those described in this Note 3.
Recently adopted accounting pronouncements	Recently adopted accounting pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for income Taxes, which is intended to simply various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in ASC 740 and also clarify and amend existing guidance to improve consistent application. This ASU is effect for the Company beginning on January 1, 2021. We adopted this pronouncement as of January 1, 2021, but this pronouncement has no effect on the income tax benefit.

Note 3 - Significant Accounti_2

Note 3 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Note 3 - Significant Accounting Policies
Estimated Useful Lives of Property, Plant and Equipment	Office equipment 3 years Machinery and equipment 5-10 years Furniture and equipment 5-7 years Laboratory equipment 5-7 years Leasehold improvements Over shorter of estimated useful life and lease term
Estimated Lives of Finite-Lived Intangible Assets	Computer software and website 3 years Trademarks 15 years Tradename 19 years Customer relationships 11 years Developed technology 15 years

Note 5 - Business Combination (

Note 5 - Business Combination (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of preliminary acquisition date fair values of the assets acquired and liabilities	Initial allocation of consideration Measurement period adjustments Updated allocation Cash and cash equivalents $ 526,439 $ 3,392 $ 529,831 Inventory 840,159 31,341 871,500 Prepaid expenses and deposits 365,308 - 365,308 Trade receivables 268,342 - 268,342 Other receivables - 150,000 150,000 Property and equipment 124,904 - 124,904 Intangible Assets (estimated useful life) - - - Developed technology (15 years) 8,650,000 - 8,650,000 Trade name (19 years) 2,350,000 - 2,350,000 Customer relationships (11 years) 22,650,000 - 22,650,000 Other Assets 68,882 265,000 333,882 Total assets acquired 35,844,034 449,733 36,293,767 Accounts payable and accrued liabilities 1,113,175 (542,439 ) 570,736 Income tax payable 43,700 - 43,700 Deferred revenue 60,675 - 60,675 Liability for contracts with customers 331,713 - 331,713 Deferred tax liabilities 7,137,789 (900,000) 6,237,789 Other non current liabilities 142,669 265,000 407,669 Total liabilities assumed 8,829,721 (1,177,439 ) 7,652,282 Net assets acquired, excluding goodwill 27,014,313 1,627,172 28,641,485 Goodwill 44,914,937 (1,627,172 ) 43,287,765 Net assets acquired $ 71,929,250 $ - $ 71,929,250 Year Ended December 31, 2021 2020 Net revenue $ 12,669,574 $ 7,077,966 Net losses (18,424,357 ) (17,335,497 )
Schedule of pro forma financial information
PulseVet [Member]
Schedule of pro forma financial information	Year ended December 31, 2021 2020 Adjustments to net revenues PulseVet preacquistion revenues $ 8,536,451 $ 7,077,966 Adjustments to net income PulseVet preacquistion net losses (41,187 ) (423,713 )

Note 6 - Inventory (Tables)

Note 6 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2021
Note 6 - Inventory
6. Inventory (Tables)	Diagnostics Therapeutics Consolidated Raw Materials $ - $ 890,446 $ 890,446 Finished Goods - 139,996 139,996 Purchased Inventory 1,848,495 - 1,848,495 Total 1,848,495 1,030,442 2,878,937 - Reserves (8,855 ) (22,097 ) (30,952 ) Inventory, Net $ 1,839,640 $ 1,008,345 $ 2,847,985

Note 7 - Prepaid expenses, de_2

Note 7 - Prepaid expenses, deposits and deferred financing costs (Tables)	12 Months Ended
	Dec. 31, 2021
Note 7 - Prepaid expenses, deposits and deferred financing costs
Schedule of Prepaid Expenses and Deposits	December 31, December 31, 2021 2020 Deposits $ 1,339,862 $ 1,455,119 Prepaid marketing 83,347 26,330 Prepaid insurance 598,668 184,154 Other 214,043 76,135 Total $ 2,235,920 $ 1,741,738

Note 8 - Property and Equipme_2

Note 8 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Note 8 - Property and Equipment
Schedule of Property and equipment	December 31, December 31, 2021 2020 Machinery and office equipment $ 1,466,778 $ 364,165 Furniture and equipment 110,244 121,281 Laboratory equipment 225,330 234,087 Leasehold improvements 287,451 571,460 2,089,803 1,290,993 Accumulated depreciation and amortization 884,257 707,986 Net property and equipment $ 1,205,546 $ 583,007

Note 9 - Intangible Assets (Tab

Note 9 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Note 9 - Intangible Assets
Schedule of Finite-Lived Intangible Assets	December 31, December 31, 2021 2020 Computer software $ 28,097 $ 22,882 Trademarks 16,235 16,236 Website 889,456 513,680 Tradename 2,350,000 - Customer Relationships 22,650,000 - Technology 8,650,000 - 34,583,788 552,798 Accumulated amortization 1,064,228 190,135 Net intangibles $ 33,519,560 $ 362,663
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated future amortization of intangible assets is as follows: 2022 $ 2,946,754 2023 2,772,784 2024 2,767,546 2025 2,760,517 2026 and beyond 22,271,959 Total $ 33,519,560

Note 10 - Leases (Tables)

Note 10 - Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Note 10 - Leases
Lessee, Operating Lease, Right of Use Asset and Lease Liabilities	2021 2020 Right-of-use asset Cost Aggregate lease commitments $ 1,778,798 $ 2,067,505 Less: impact of present value (154,695 ) (513,894 ) Balance 1,624,103 1,553,611 Reduction in right-of-use asset Straight line amortization 346,457 379,043 Interest (42,164 ) (144,148 ) Balance 304,293 234,895 Net book value $ 1,319,810 $ 1,318,716 Lease liabilities Additions $ 1,647,449 $ 1,553,611 Payments (310,726 ) (356,972 ) Interest 42,163 144,147 Total lease liabilities at December 31, 2021 1,378,886 1,340,786 Current portion of lease liabilities 414,695 252,788 Long term portion of lease liabilities 964,191 1,087,998 Total lease liabilities at December 31, 2021 $ 1,378,886 $ 1,340,786
Lessee, Operating Lease, Liability, Maturity	Total remaining undiscounted lease liabilities related to the above lease are as follows: 2022 $ 461,726 2023 475,579 2024 489,845 2025 40,920 Total $ 1,468,070

Note 12 - Preferred stock (Tabl

Note 12 - Preferred stock (Tables)	12 Months Ended
	Dec. 31, 2021
Note 12 - Preferred stock
Schedule of Preferred Stock	Number of Preferred preferred stock stock amount Balance at December 31, 2019 12 $ 11,961,397 Balance at December 31, 2020 12 $ 11,961,397 Stock exchanged (12 ) $ (11,961,397 ) Balance at December 31, 2021 - $ -

Note 14 - Stock-based compens_2

Note 14 - Stock-based compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Note 14 - Stock-based compensation
Share-based Payment Arrangement, Option, Activity	Number of Weighted Avg options Exercise Price Balance at December 31, 2020 39,604,515 $ 0.36 Stock options granted 24,750,000 0.72 Stock options exercised 7,022,776 0.25 Unvested stock options forfeited 2,580,000 0.54 Vested stock options expired 4,034,015 1.52 Balance at December 31, 2021 50,717,724 $ 0.45 Vested at December 31, 2021 18,347,474 $ 0.28
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) March 14, 2020 0.19 3,018,557 2,025,807 992,750 3.20 July 9, 2020 0.18 175,000 87,500 87,500 3.52 August 25, 2020 0.13 20,000 - 20,000 3.65 September 29, 2020 0.11 225,000 225,000 - 3.75 October 1, 2020 0.11 266,667 116,667 150,000 3.75 October 20, 2020 0.09 20,000 10,000 10,000 3.81 December 31, 2020 0.23 23,442,500 14,682,500 8,760,000 9.00 February 26, 2021 1.87 600,000 150,000 450,000 9.16 March 1, 2021 2.06 200,000 50,000 150,000 9.17 March 8, 2021 1.88 200,000 50,000 150,000 9.19 March 15, 2021 2.49 200,000 50,000 150,000 9.21 May 12, 2021 0.78 3,600,000 850,000 2,750,000 9.36 May 14, 2021 0.75 3,200,000 50,000 3,150,000 9.37 August 11, 2021 0.57 1,300,000 - 1,300,000 9.61 August 18, 2021 0.50 200,000 - 200,000 9.63 August 23, 2021 0.50 100,000 - 100,000 9.65 September 13, 2021 0.57 800,000 - 800,000 9.70 September 27, 2021 0.54 500,000 - 500,000 9.74 October 1, 2021 0.58 12,650,000 - 12,650,000 9.75 Balance at December 31, 2021 50,717,724 18,347,474 32,370,250
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	February 26, 2021 March 1, 2021 March 8, 2021 Volatility 117 % 117 % 117 % Risk-free interest rate 0.95 % 0.92 % 1.07 % Expected life 10 years 10 years 10 years Dividend yield 0 % 0 % 0 % Common share price $ 1.87 $ 2.06 $ 1.88 Strike price $ 1.87 $ 2.06 $ 1.88 Forfeiture rate zero zero zero May 12, 2021 August 11, 2021 August 23, 2021 Volatility 118 % 116 % 116 % Risk-free interest rate 1.11 % 0.96 % 0.92 % Expected life 6.21 - 6.22 Years 6.18 - 6.25 6.25 Dividend yield 0 % 0 % 0 % Common share price $ 0.78 $ 0.56 $ 0.50 Strike price $ 0.78 $ 0.57 $ 0.50 Forfeiture rate zero zero zero September 27, 2021 October 1, 2021 Volatility 116 % 116 % Risk-free interest rate 1.14 % 1.10 % Expected life 6.25 6.25 Dividend yield 0 % 0 % Common share price $ 0.54 $ 0.57 Strike price $ 0.54 $ 0.58 Forfeiture rate zero zero

Note 15 - Warrants (Tables)

Note 15 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Note 15 - Warrants (Tables)
Schedule of Warrants Outstanding	Original Issue date Exercise Price Warrants Outstanding Weighted Average Remaining Life February 14, 2020 0.15 197,917 3.12 April 9, 2020 0.15 363,501 3.27 May 29, 2020 0.15 120,000 0.41 July 7, 2020 0.16 231,000 0.52 Balance at December 31, 2021 912,418
Schedule of Cumulative Warrant Exercises	Warrants Warrant series exercised Amount Series A 21,677,084 $ 4,293,229 Series B 17,969,833 2,695,475 Series C 133,213,333 19,982,000 Series D 187,269,000 29,963,040 Subtotal 360,129,250 56,933,744 Common stock subscribed - (459,600 ) Total 360,129,250 $ 56,474,144

Note 16 - Income taxes (Tables)

Note 16 - Income taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Note 16 - Income taxes
Schedule of Deferred Tax Assets and Liabilities	December 31, 2021 December 31, 2020 Loss before income taxes $ (20,716,224 ) $ (16,911,784 ) Expected income tax benefit 4,764,732 4,058,828 Difference in foreign rates (180,419 ) 74,847 Tax rate changes and other adjustments (48,230 ) (1,540,539 ) Stock based compensation and nondeductible expenses (1,394,102 ) (407,689 ) Foreign accrual property income (15,870 ) (210,605 ) Prior period adjustment (161,752 ) (32,518 ) Share issuance costs recorded in equity 3,284,610 1,282,179 Section 382 derecognition (4,343,851 ) - Change in valuation allowance 427,936 (3,224,503 ) Total Income tax benefit $ 2,333,054 $ - 2021 2020 Deferred tax assets Intangible assets - licenses $ 4,236,137 $ 4,236,169 Share issuance costs 3,425,321 1,148,179 Reserves 180,700 28,784 Non-capital loss carried forward - Canada 8,386,587 6,182,002 Net operating losses carried forward - US 2,591,577 5,091,162 Investment tax credits 30,000 27,328 Operating leases 4,022 345,937 Other - 466 Total deferred tax assets 18,854,344 17,060,027 Deferred tax liabilities Property and equipment (138,918 ) (94,218 ) Right-of-use asset - (340,242 ) Intangibles (6,078,850 ) - Other (148,257) - Total deferred tax liabilities (6,366,025 ) (434,460 ) Valuation allowance 16,197,631 16,625,567 Net deferred tax liability $ (3,709,312 ) $ -
Schedule of Effective Income Tax Rate Reconciliation	2036 $ 3,763,071 2037 $ 4,278,944 2038 $ 5,416,916 2039 $ 6,773,728 2040 $ 7,417,578 2041 $ 9,629,482 Total $ 37,279,719 2035 $ 856,301 2036 $ 1,484,636 2037 $ 3,831,764 indefinitely (subject to 80% limitation) $ 22,005,181 Derecognized under Section 382 $ (20,975,994 ) Total $ 7,201,888

Note 18 - Segmented informati_2

Note 18 - Segmented information (Tables)	12 Months Ended
	Dec. 31, 2021
Note 18 - Segmented information (Tables)
Schedule of long-lived assets	Diagnostics Therapeutics Consolidated Net Revenue $ 125,361 $ 4,007,762 $ 4,133,123 Operating (loss) income (22,414,463) 1,046,466 (21,367,997) Net interest income 347,611 3,782 351,393 Other gains 47,929 3,932 51,861 (Loss) income before income taxes $ (21,740,247 ) $ 1,024,023 $ (20,716,224 ) Total assets $ 199,556,729 $ 80,842,564 $ 280,399,293 Depreciation and amortization 425,981 713,608 1,139,589 Capital expenditures $ 523,656 2,293 $ 525,949
Long-lived Assets by Geographic Areas	December 31, December 31, 2021 2020 Canada $ 170,601,082 $ 53,160,701 US 109,798,211 12,983,333 Total assets $ 280,399,293 $ 66,144,034 Total US property and equipment $ 1,205,546 $ 583,007 Total US right-of-use asset $ 1,319,810 $ 1,318,716

Note 19 - Loss per share (Table

Note 19 - Loss per share (Tables)	12 Months Ended
	Dec. 31, 2021
Note 18 - Segmented information (Tables)
Schedule of Earnings Per Share, Basic and Diluted	For the year ended For the year ended December 31, 2021 December 31, 2020 Numerator Net loss for the year $ (18,383,170 ) $ (16,911,784 ) Charge to retained earnings for preferred share exchange (32,038,603 ) - Denominator 956,533,761 364,444,664 Weighted average shares - basic - - Warrants - - Stock options - - Denominator for diluted loss per share 956,533,761 364,444,664 Loss per share - basic and diluted $ (0.05 ) $ (0.05 )

Significant Accounting Polici_2

Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2021
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life	Over shorter of estimated useful life and lease term
Office Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Furniture And Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture And Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Laboratory Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Laboratory Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Machinery And Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Machinery And Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	10 years

Significant Accounting Polici_3

Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2021
Computer Software and Website, Intangible Asset [Member]
Intangible assets indefinite useful lives (Year)	3 years
Tradename [Member]
Intangible assets indefinite useful lives (Year)	19 years
Customer Relationships [Member]
Intangible assets indefinite useful lives (Year)	11 years
Trademarks [Member]
Intangible assets indefinite useful lives (Year)	15 years
Developed Technology Rights [Member]
Intangible assets indefinite useful lives (Year)	15 years

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative)	12 Months Ended
	Dec. 31, 2021USD ($)
Consolidated Balance Sheets
Net revenue	$ 4,133,123
Consumables Revenue	125,361
Instruments, consumables and services Revenues	1,792,865
Allowance for doubtful accounts	34,000
Revenue from trodes	2,072,582
Revenue from warranties and services	28,959
Other revenue	$ 113,356

Business Combination (Details)

Business Combination (Details) - USD ($)	Dec. 31, 2021	Oct. 01, 2021	Dec. 31, 2020
Other receivables	$ 450,081		$ 146,207
Goodwill	$ 43,287,765		$ 0
Initial Allocation Of Consideration [Member]
Cash and cash equivalents		$ 526,439
Inventory		840,159
Prepaid expenses and deposits		365,308
Trade receivables		268,342
Other receivables		0
Property and equipment		124,904
Intangible assets developed technology		8,650,000
Intangible assets trade name		2,350,000
Intangible assets customer relationships		22,650,000
Other Assets		68,882
Total assets acquired		35,844,034
Accounts payable and accrued liabilities		1,113,175
Income tax payable		43,700
Deferred revenue		60,675
Liability for contracts with customers		331,713
Deferred tax liabilities		7,137,789
Other non current liabilities		142,669
Total liabilites assumed		8,829,721
Net assets acquired, excluding goodwill		27,014,313
Goodwill		44,914,937
Net assets acquired		71,929,250
Measurement Period Adjustments [Member]
Cash and cash equivalents		3,392
Inventory		31,341
Prepaid expenses and deposits		0
Trade receivables		0
Other receivables		150,000
Property and equipment		0
Intangible assets developed technology		0
Intangible assets trade name		0
Intangible assets customer relationships		0
Other Assets		265,000
Total assets acquired		449,733
Accounts payable and accrued liabilities		542,439
Income tax payable		0
Deferred revenue		0
Liability for contracts with customers		0
Deferred tax liabilities		900,000
Other non current liabilities		265,000
Total liabilites assumed		1,177,439
Net assets acquired, excluding goodwill		1,627,172
Goodwill		(1,627,172)
Net assets acquired		0
Updated Allocation [Member]
Cash and cash equivalents		529,831
Inventory		871,500
Prepaid expenses and deposits		365,308
Trade receivables		268,342
Other receivables		150,000
Property and equipment		124,904
Intangible assets developed technology		8,650,000
Intangible assets trade name		2,350,000
Intangible assets customer relationships		22,650,000
Other Assets		333,882
Total assets acquired		36,293,767
Accounts payable and accrued liabilities		570,736
Income tax payable		43,700
Deferred revenue		60,675
Liability for contracts with customers		331,713
Deferred tax liabilities		6,237,789
Other non current liabilities		407,669
Total liabilites assumed		7,652,282
Net assets acquired, excluding goodwill		28,641,485
Goodwill		43,287,765
Net assets acquired		$ 71,929,250

Business Combination (Details 1

Business Combination (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Note 5 - Business Combination
Net revenue	$ 12,669,574	$ 7,077,966
Net losses	$ (18,424,357)	$ (17,335,497)

Business Combination (Details 2

Business Combination (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Net revenue	$ 12,669,574	$ 7,077,966
Net losses	(18,424,357)	(17,335,497)
PulseVet [Member]
Net revenue	8,536,451	7,077,966
Net losses	$ (41,187)	$ (423,713)

Business Combination (Details n

Business Combination (Details narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Oct. 01, 2021
Purchase price for acquisition in cash			$ 71,929,250,000,000
Ownership interest percentage rate			100.00%
Goodwill	$ 43,287,765	$ 0
Revenue	4,133,123
Net loss	(18,383,170)	(16,911,784)
Amortization of identifiable assets	874,093	$ 224,106
PulseVet [Member]
Goodwill			$ 43,287,765
Revenue	4,007,762
Net loss	453,697
Amortization of identifiable assets	$ 689,860

Inventory (Details)

Inventory (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Raw Materials	$ 890,446
Finished Goods	139,996
Purchased Inventory	1,848,495
Total	2,878,937
Reserves	(30,952)
Inventory, Net	2,847,985	$ 0
Diagnostics [Member]
Raw Materials	0
Finished Goods	0
Purchased Inventory	1,848,495
Total	1,848,495
Reserves	(8,855)
Inventory, Net	1,839,640
Therapeutics [Member]
Raw Materials	890,446
Finished Goods	139,996
Purchased Inventory	0
Total	1,030,442
Reserves	(22,097)
Inventory, Net	$ 1,008,345

Prepaid Expenses Deposits and D

Prepaid Expenses Deposits and Deferred Financing Costs (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Consolidated Balance Sheets
Deposits	$ 1,339,862	$ 1,455,119
Prepaid marketing	83,347	26,330
Prepaid insurance	598,668	184,154
Other	214,043	76,135
Total	$ 2,235,920	$ 1,741,738

Prepaid Expenses Deposits and_2

Prepaid Expenses Deposits and Deferred Financing Costs (Details Narrative)	Dec. 31, 2020USD ($)
Consolidated Balance Sheets
Prepaid Expenses and Deposits, Noncurrent	$ 0
Prepaid insurance non current assets	$ 0

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment, Gross	$ 2,089,803	$ 1,290,993
Accumulated depreciation and amortization	884,257	707,986
Net property and equipment	1,205,546	583,007
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	287,451	571,460
Machinery And Office Equipment [Member]
Property, Plant and Equipment, Gross	1,466,778	364,165
Furniture And Equipment [Member]
Property, Plant and Equipment, Gross	110,244	121,281
Laboratory Equipment [Member]
Property, Plant and Equipment, Gross	$ 225,330	$ 234,087

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidated Balance Sheets
Deprecition expense	$ 265,496	$ 305,914

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Net intangibles	$ 33,519,560	$ 362,663
Accumulated Amortization	1,064,228	190,135
Intangible Assets	34,583,788	552,798
Tradename [Member]
Intangible Assets	2,350,000	0
Customer Relationships [Member]
Intangible Assets	22,650,000	0
Trademarks [Member]
Intangible Assets	16,235	16,236
Computer Software, Intangible Asset [Member]
Intangible Assets	28,097	22,882
Website [Member]
Intangible Assets	889,456	513,680
Technology [Member]
Intangible Assets	$ 8,650,000	$ 0

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Consolidated Balance Sheets
2022	$ 2,946,754
2023	2,772,784
2024	2,767,546
2025	2,760,517
2026 and beyond	22,271,959
Total	$ 33,519,560	$ 362,663

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Note 9 - Intangible Assets
Amortization expense	$ 874,093	$ 224,106

Leases (Details)

Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases (Details)
Total lease liabilities at December 31, 2021	$ 1,378,886	$ 1,340,786
Long term portion of lease liabilities	964,191	1,087,998
Current portion of lease liabilities	414,695	252,788
Additions	1,647,449	1,553,611
Payments	(310,726)	(356,972)
Interest	42,163	144,147
Straight line amortization	346,457	379,043
Interest	(42,164)	(144,148)
Total lease liabilities at December 31, 2021	1,378,886	1,340,786
Reduction in right-of-use asset, balance	304,293	234,895
Net book value	1,319,810	1,318,716
Aggregate lease commitments	1,778,798	2,067,505
Less: impact of present value and lease modification	(154,695)	(513,894)
Cost, balance	$ 1,624,103	$ 1,553,611

Leases (Details 1)

Leases (Details 1)	Dec. 31, 2021USD ($)
Leases (Details)
2022	$ 461,726
2023	475,579
2024	489,845
2025	40,920
Total	$ 1,468,070

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 15, 2021	Dec. 31, 2021	Dec. 31, 2020
Operating Lease, Right-of-Use Asset		$ 1,319,810	$ 1,318,716
Lease Agreement with Wickfield Phoenix LLC [Member]
Operating Lease, Expense		411,315	379,041
Lessee, Operating Lease, Term of Contract (Month)	41 years
Monthly Rent Payment	$ 10,009
Lessee, Operating Lease, Discount Rate	3.95%
Gain (loss) on Operating Lease, Right-of-Use Assets	$ 365,840
Rent expense, month-to-month leases			4,331
Lease Agreement with Wickfield Phoenix LLC [Member] | Minimum [Member]
Monthly Rent Payment	$ 4,580	$ 32,452
Lease Agreement with Wickfield Phoenix LLC [Member] | February 1, 2020 [Member]
Lessee, Operating Lease, Term of Contract (Month)		60 years
Monthly Rent Payment		$ 36,525
Lessee, Operating Lease, Discount Rate		12.00%
Operating Lease, Right-of-Use Asset		$ 1,553,611
Lease Agreement with Wickfield Phoenix LLC [Member] | February 1, 2021 [Member]
Lessee, Operating Lease, Term of Contract (Month)		48 years
Monthly Rent Payment		$ 30,911
Lessee, Operating Lease, Discount Rate		3.95%
Gain (loss) on Operating Lease, Right-of-Use Assets		$ 731
Operating Lease, Right-of-Use Asset, Lease Modification		1,258,263
Operating Lease, Liability, Total		1,281,609
Lease Agreement with Wickfield Phoenix LLC [Member] | February 1, 2021 [Member] | Minimum [Member]
Monthly Rent Payment		12,039
Lease Agreement with Wickfield Phoenix LLC [Member] | Research and Development Expense [Member]
Operating Lease, Expense		94,544	83,425
Lease Agreement with Wickfield Phoenix LLC [Member] | General and Administrative Expense [Member]
Operating Lease, Expense		315,771	295,616
Lease Modification [Member]
Gain (loss) on Operating Lease, Right-of-Use Assets			$ 59,097
Lease Cancellation [Member]
Increase (Decrease) in Prepaid Rent		$ 1,002,113

Loan arrangements (Details Narr

Loan arrangements (Details Narrative) - USD ($)	Jun. 13, 2021	Apr. 30, 2020	Mar. 27, 2020	Oct. 18, 2017
Emergency economic relief			$ 2,000,000,000,000
Temporarily guarantee loans description			The Program provides for 100% federally guaranteed loans to small businesses to allow employers to keep workers employed and maintain payroll
Proceeds from Short-term Debt, Total		$ 527,360
Loan Arrangement With Shareholder [Member]
Debt Instrument, Interest Rate, Stated Percentage				14.00%
Debt Instrument, Term (Year)				5 years
Debt Agreement, Maximum Borrowing Capacity				$ 5,000,000
Paycheck Protection Program CARES Act [Member]
Gain (Loss) on Extinguishment of Debt, Total	$ 533,414
Gain (Loss) on Extinguishment of Debt, Portion Attributable to Accrued Interest	$ 6,054

Preferred stock (Details)

Preferred stock (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance, amount	$ 0	$ 11,961,397
Balance, number (in shares)	0	12
Series Preferred Shares [Member]
Balance, amount	$ 0	$ 11,961,397	$ 11,961,397
Balance, number (in shares)		12	12
Stock redemption (in shares)	(12)
Stock redemption	$ (11,961,397)

Preferred stock (Details Narrat

Preferred stock (Details Narrative) - USD ($)	Mar. 07, 2021	Dec. 31, 2021	Dec. 31, 2020
Charge to retained earnings for preferred share exchange		$ (32,038,603)	$ 0
Conversion of Stock, Amount Issued		$ 11,961,397
Preferred Stock, Shares Authorized (in shares)		20	20
Preferred Stock, Stated Value Per Share (in dollars per share)		$ 0	$ 11,961,397
Series 1 Preferred Shares [Member]
Preferred Stock, Shares Authorized (in shares)		20
Net Sales Payments, Percentage of Sales		9.00%
Fundamental transaction description		defined to include an amalgamation, merger or other business combination transaction involving our company in which our shareholders do not have the right to cast more than 50% of the votes that may be cast for the election of directors, or a sale, lease or other disposition of the properties and/or assets of our company as an entirety or substantially as an entirety to a third party), the holders of the Series 1 Preferred Shares will be entitled to receive consideration for their Series 1 Preferred Shares equal to a multiple of the stated value of the Series 1 Preferred Shares ranging from 5.0 to 9.0 depending on the timing of the fundamental transaction
Preferred Stock, Stated Value Per Share (in dollars per share)		$ 1,000,000
Redemption of Preferred Shares for Common Shares [Member]
Conversion of Stock, Amount Issued	$ 44,000,000
Conversion of Stock, Shares Issued (in shares)	24,719,101

Common stock (Details Narrative

Common stock (Details Narrative) - USD ($)	Feb. 08, 2021	Jul. 07, 2020	Apr. 09, 2020	Jul. 31, 2020	Jun. 30, 2020	May 29, 2020	Feb. 29, 2020	Feb. 14, 2020	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 0.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								20,833,334
Class of Warrant or Right, Issued During Period (in shares)								20,833,334
Class of Warrant or Right, Issued During Period, Value								$ 794,345
Class of Warrant or Right, Period Exerciseable (Month)								6 months
Issuance of Common Shares and Warrants, Direct Costs of Issuance		$ 2,268,215	$ 582,977			$ 1,908,202	$ 348,220
Stock Issued During Period, Shares, Exercise of Warrants and Pre-funded Warrants (in shares)				24,984,492	12,162,492
Proceeds from Issuance of Common Stock									$ 199,525,000	$ 56,496,283
Stock Issued During Period, Value, New Issues									11,810	$ 0
Common Stocks [Member]
Issuance of Common Shares and Warrants, Direct Costs of Issuance		1,224,218	428,283			1,088,876	238,217		$ (14,280,914)
Stock Issued During Period, Value, New Issues	$ 199,525,000
Additional Paid-in Capital [Member]
Issuance of Common Shares and Warrants, Direct Costs of Issuance		1,043,997	154,694			$ 819,327	110,003
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)						121,163,333
Proceeds from Issuance of Common Stock			2,942,248
Proceeds from Issuance or Sale of Equity, Total		29,997,500	$ 4,000,000			$ 19,998,783
Stock Issued During Period, Value, New Issues		$ 16,290,941				$ 11,336,422
Offering Price (in dollars per share)			$ 0.12
Shares Issued, Number of Warrants Per Share (in shares)			$ 0.5
Stock and Warrants Issued During Period, Shares, New Issues (in shares)			33,333,334
The Common Shares Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	91,315,790
Proceeds from Issuance of Common Stock	$ 199,525,000
Shares Issued, Price Per Share (in dollars per share)	$ 1.90
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)								20,833,334
Proceeds from Issuance or Sale of Equity, Total								$ 2,500,000
Stock Issued During Period, Value, New Issues								$ 1,705,655
Shares Issued, Price Per Share (in dollars per share)								$ 0.12
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	13,697,368
Public Offering with One Common Share and One Series C Warrant [Member]
Offering Price (in dollars per share)						$ 0.15
Series D Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.1599
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		187,500,000
Class of Warrant or Right, Issued During Period (in shares)		25,000,000
Proceeds from Issuance of Warrants		$ 11,376,575
Stock Issued During Period, Shares, New Issues (in shares)		162,500,000
Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15					$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,666,667					1,041,667
Class of Warrant or Right, Issued During Period (in shares)			1,666,667					1,041,667
Adjustments to Equity, Warrant Issued			$ 161,714				12,162,492
Placement Agent Warrants [Member] | Common Stocks [Member]
Adjustments to Equity, Warrant Issued			118,951				35,816
Placement Agent Warrants [Member] | Additional Paid-in Capital [Member]
Adjustments to Equity, Warrant Issued			$ 42,763				$ 16,680
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			16,666,667
Class of Warrant or Right, Issued During Period (in shares)			16,666,667
Proceeds from Issuance of Warrants			$ 1,057,752
Series C Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						133,333,333
Class of Warrant or Right, Issued During Period (in shares)						133,333,333
Proceeds from Issuance of Warrants						$ 7,582,072
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)						1
Pre-funded Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.0001				$ 0.0001
Class of Warrant or Right, Issued During Period (in shares)						12,170,000
Proceeds from Issuance of Warrants		$ 2,329,983				$ 1,080,289
Public Offering with One Pre-funded Warrant and One Series C Warrant [Member]
Offering Price (in dollars per share)						$ 0.1499

Stock-based compensation (Detai

Stock-based compensation (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidated Balance Sheets
Number of Options Options Outstanding (in shares)	39,604,515
Weighted Avg Exercise Price Options Outstanding (in dollars per share)	$ 0.36
Number of Options Stock options granted (in shares)	24,750,000	35,471,000
Weighted Avg Exercise Price Stock options granted (in dollars per share)	$ 0.72
Stock options exercised (in shares)	7,022,776
Weighted Avg Exercise Price Stock options exercised (in dollars per share)	$ 0.25
Number of Options Stock options forfeited (in shares)	2,580,000
Weighted Avg Exercise Price Stock options forfeited (in dollars per share)	$ 0.54
Number of Options Stock options cancelled (in shares)	4,034,015
Weighted Avg Exercise Price Stock options cancelled (in dollars per share)	$ 1.52
Number of Options Options Outstanding (in shares)	50,717,724	39,604,515
Weighted Avg Exercise Price Options Outstanding (in dollars per share)	$ 0.45	$ 0.36
Number of Options Options Vested (in shares)	18,347,474
Weighted Avg Exercise Price Vested (in dollars per share)	$ 0.28

Stock-based compensation (Det_2

Stock-based compensation (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of Options (in shares)	50,717,724	39,604,515
Number of vested options outstanding (in shares)	18,347,474
Number of unvested options outstanding (in shares)	32,370,250
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.72
March 14, 2020 [Member] | Options 1 [Member]
Number of Options (in shares)	3,018,557
Number of vested options outstanding (in shares)	2,025,807
Number of unvested options outstanding (in shares)	992,750
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.19
Weighted Avg Remaining Life (Year)	3 years 2 months 12 days
July 9, 2020 [Member] | Options 2 [Member]
Number of Options (in shares)	175,000
Number of vested options outstanding (in shares)	87,500
Number of unvested options outstanding (in shares)	87,500
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.18
Weighted Avg Remaining Life (Year)	3 years 6 months 7 days
August 25, 2020 [Member] | Options 3 [Member]
Number of Options (in shares)	20,000
Number of unvested options outstanding (in shares)	20,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.13
Weighted Avg Remaining Life (Year)	3 years 7 months 24 days
September 29, 2020 [Member] | Options 4 [Member]
Number of Options (in shares)	225,000
Number of vested options outstanding (in shares)	225,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.11
Weighted Avg Remaining Life (Year)	3 years 9 months
October 1, 2020 [Member] | Options 5 [Member]
Number of Options (in shares)	266,667
Number of vested options outstanding (in shares)	116,667
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.11
Weighted Avg Remaining Life (Year)	3 years 9 months
October 20, 2020 [Member] | Options 6 [Member]
Number of Options (in shares)	20,000
Number of vested options outstanding (in shares)	10,000
Number of unvested options outstanding (in shares)	10,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.09
Weighted Avg Remaining Life (Year)	3 years 9 months 21 days
December 31, 2020 [Member] | Options 7 [Member]
Number of Options (in shares)	23,442,500
Number of vested options outstanding (in shares)	14,682,500
Number of unvested options outstanding (in shares)	8,760,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.23
Weighted Avg Remaining Life (Year)	9 years
February 26, 2021 [Member] | Options 8 [Member]
Number of Options (in shares)	60,000,000,000
Number of vested options outstanding (in shares)	150,000
Number of unvested options outstanding (in shares)	4,500,000,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 1.87
Weighted Avg Remaining Life (Year)	9 years 1 month 28 days
March 1, 2021 [Member] | Options 9 [Member]
Number of Options (in shares)	200,000
Number of vested options outstanding (in shares)	50,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 2.06
Weighted Avg Remaining Life (Year)	9 years 2 months 1 day
March 8, 2021 [Member] | Options 10 [Member]
Number of Options (in shares)	200,000
Number of vested options outstanding (in shares)	50,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 1.88
Weighted Avg Remaining Life (Year)	9 years 2 months 8 days
March 15, 2021 [Member] | Options 11 [Member]
Number of Options (in shares)	200,000
Number of vested options outstanding (in shares)	50,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 2.49
Weighted Avg Remaining Life (Year)	9 years 2 months 15 days
May 12, 2021 [Member] | Options 12 [Member]
Number of Options (in shares)	3,600,000
Number of vested options outstanding (in shares)	850,000
Number of unvested options outstanding (in shares)	2,750,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.78
Weighted Avg Remaining Life (Year)	9 years 4 months 9 days
May 14, 2021 [Member] | Options 13 [Member]
Number of Options (in shares)	3,200,000
Number of vested options outstanding (in shares)	50,000
Number of unvested options outstanding (in shares)	3,150,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.75
Weighted Avg Remaining Life (Year)	9 years 4 months 13 days
August 11, 2021 [Member] | Options 14 [Member]
Number of Options (in shares)	1,300,000
Number of unvested options outstanding (in shares)	1,300,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.57
Weighted Avg Remaining Life (Year)	9 years 7 months 9 days
August 18, 2021 [Member] | Options 15 [Member]
Number of Options (in shares)	200,000
Number of unvested options outstanding (in shares)	200,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.50
Weighted Avg Remaining Life (Year)	9 years 7 months 17 days
August 23, 2021 [Member] | Options 16 [Member]
Number of Options (in shares)	100,000
Number of unvested options outstanding (in shares)	100,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.50
Weighted Avg Remaining Life (Year)	9 years 7 months 24 days
September 13, 2021 [Member] | Options 17 [Member]
Number of Options (in shares)	800,000
Number of unvested options outstanding (in shares)	800,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.57
Weighted Avg Remaining Life (Year)	9 years 8 months 12 days
September 27, 2021 [Member] | Options 18 [Member]
Number of Options (in shares)	500,000
Number of unvested options outstanding (in shares)	500,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.54
Weighted Avg Remaining Life (Year)	9 years 8 months 26 days
October 01, 2021 [Member] | Options 19 [Member]
Number of Options (in shares)	12,650,000
Number of unvested options outstanding (in shares)	12,650,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.58
Weighted Avg Remaining Life (Year)	9 years 9 months

Stock-based compensation (Det_3

Stock-based compensation (Details 2) - $ / shares	Oct. 01, 2021	Sep. 27, 2021	Aug. 23, 2021	Aug. 11, 2021	May 12, 2021	Mar. 08, 2021	Mar. 01, 2021	Feb. 26, 2021
Volatility	116.00%	116.00%	116.00%	116.00%	118.00%	117.00%	117.00%	117.00%
Risk-free interest rate	1.10%	1.14%	0.92%	0.96%	1.11%	1.07%	0.92%	0.95%
Expected life	6 years 2 months 30 days	6 years 3 months	6 years 3 months			10 years	10 years	10 years
Dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common share price (in dollars per share)	$ 0.57	$ 0.54	$ 0.50	$ 0.56	$ 0.78	$ 1.88	$ 2.06	$ 1.87
Strike price (in dollars per share)	$ 0.58	$ 0.54	$ 0.50	$ 0.57	$ 0.78	$ 1.88	$ 2.06	$ 1.87
Forfeiture rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Expected life				6 years 2 months 19 days	6 years 2 months 15 days
Maximum [Member]
Expected life				6 years 3 months	6 years 2 months 19 days

Stockbased Compensation (Detail

Stockbased Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidated Balance Sheets
Sharebased Compensation Arrangement by Sharebased Payment Award Options Grants in Period Gross (in shares)	24,750,000	35,471,000
Sharebased Compensation Arrangement by Sharebased Payment Award Award Vesting Period (Year)	4 years	4 years
Sharebased Compensation Arrangement by Sharebased Payment Award Expiration Period (Year)	10 years	5 years
Sharebased Compensation Arrangement by Sharebased Payment Award Options Exercises in Period (in shares)	7,022,776	0
Proceeds from Stock Options Exercised	$ 1,768,461
Reclassification of additional paid-in-capital to common stock	1,051,225
Sharebased Payment Arrangement Expense	$ 7,092,031	$ 1,656,184

Warrants (Details)

Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Feb. 14, 2020
Warrants and Rights, Outstanding (in shares)	912,418
Warrant, exercise price (in dollars per share)		$ 0.20
Warrant Two [Member]
Warrants and Rights, Outstanding (in shares)	197,917
Warrant, exercise price (in dollars per share)	$ 0.15
Warrants, weighted average remaining life (Year)	3 years 1 month 13 days
Warrant Three [Member]
Warrants and Rights, Outstanding (in shares)	363,501
Warrant, exercise price (in dollars per share)	$ 0.15
Warrants, weighted average remaining life (Year)	3 years 3 months 7 days
Warrant Four [Member]
Warrants and Rights, Outstanding (in shares)	120,000
Warrant, exercise price (in dollars per share)	$ 0.15
Warrants, weighted average remaining life (Year)	4 months 28 days
Warrant Five [Member]
Warrants and Rights, Outstanding (in shares)	231,000
Warrant, exercise price (in dollars per share)	$ 0.16
Warrants, weighted average remaining life (Year)	6 months 7 days

Warrants (Details 1)

Warrants (Details 1)	12 Months Ended
	Dec. 31, 2021USD ($)shares
Sub Total Warrent exercised shares | shares	360,129,250
Sub Total Warrent amount	$ 56,933,744
Common stock subscribed amount	$ (459,600)
Total warrant execised | shares	360,129,250
Total Amount	$ 56,474,144
Series D Warrants [Member]
Sub Total Warrent exercised shares | shares	187,269,000
Sub Total Warrent amount	$ 29,963,040
Series B Warrants [Member]
Sub Total Warrent exercised shares | shares	17,969,833
Sub Total Warrent amount	$ 2,695,475
Series C Warrants [Member]
Sub Total Warrent exercised shares | shares	133,213,333
Sub Total Warrent amount	$ 19,982,000
Series A Warrants [Member]
Sub Total Warrent exercised shares | shares	21,677,084
Sub Total Warrent amount	$ 4,293,229

Warrants (Details Narrative)

Warrants (Details Narrative) - $ / shares	Jul. 07, 2020	Apr. 09, 2020	May 29, 2020	Feb. 14, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				20,833,334
Series D Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.1599
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	187,500,000
Warrants and Rights Outstanding, Term (Year)	2 years
Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.15		$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,666,667		1,041,667
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		16,666,667
Warrants and Rights Outstanding, Term (Year)		5 years
Series C Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			133,333,333
Warrants and Rights Outstanding, Term (Year)			2 years
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				20,833,334
Warrants and Rights Outstanding, Term (Year)				5 years 6 months
Series C Pre-funded Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			12,170,000
Series D Pre-funded Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	25,000,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Note 16 - Income taxes
Loss before income taxes	$ (20,716,224)	$ (16,911,784)
Expected income tax expense (recovery)	(4,764,732)	(4,058,828)
Difference in foreign tax rates	180,419	(74,847)
Tax rate changes and other adjustments	48,230	1,540,539
Stock based compensation and nondeductible expenses	1,394,102	407,689
Foreign accrual property income	15,870	210,605
Prior period adjustment	161,752	32,518
Share issuance costs recorded in equity	(3,284,610)	(1,282,179)
Section 382 derecognition	4,343,851	0
Change in valuation allowance	(427,936)	3,224,503
Total income tax expense	$ (2,333,054)	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets
Intangible assets licenses	$ 4,236,137	$ 4,236,169
Share issuance costs	3,425,321	1,148,179
Reserves	180,700	28,784
Noncapital losses carried forward Canada	8,386,587	6,182,002
Net operating losses carried forward US	2,591,577	5,091,162
Investment Tax Credits	30,000	27,328
Operating leases	4,022	345,937
Other	0	466
Total deferred tax assets	18,854,344	17,060,027
Deferred Tax Liabilities
Property and equipment	(138,918)	94,218
Intangible assets	(6,078,850)	0
Right of use asset	0	(340,242)
Others	(148,257)	0
Total deferred tax liabilities	(6,366,025)	(434,460)
Valuation allowance	16,197,631	16,625,567
Net deferred tax asset	$ (3,709,312)	$ 0

Income Taxes (Details 2)

Income Taxes (Details 2)	Dec. 31, 2021USD ($)
Foreign Tax Authority [Member] | Canada Revenue Agency [Member]
Non-operating loss carryforward	$ 37,279,719
Foreign Tax Authority [Member] | Canada Revenue Agency [Member] | Tax Year 2036 [Member]
Non-operating loss carryforward	3,763,071
Foreign Tax Authority [Member] | Canada Revenue Agency [Member] | Tax Year 2037 [Member]
Non-operating loss carryforward	4,278,944
Foreign Tax Authority [Member] | Canada Revenue Agency [Member] | Tax Year 2038 [Member]
Non-operating loss carryforward	5,416,916
Foreign Tax Authority [Member] | Canada Revenue Agency [Member] | Tax Year 2039 [Member]
Non-operating loss carryforward	6,773,728
Foreign Tax Authority [Member] | Canada Revenue Agency [Member] | Tax Year 2040 [Member]
Non-operating loss carryforward	7,417,578
Foreign Tax Authority [Member] | Canada Revenue Agency [Member] | Tax Year2041 [Member]
Non-operating loss carryforward	9,629,482
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Non-operating loss carryforward	7,201,888
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2036 [Member]
Non-operating loss carryforward	1,484,636
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2037 [Member]
Non-operating loss carryforward	3,831,764
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2035 [Member]
Non-operating loss carryforward	856,301
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Indefinitely [Member]
Non-operating loss carryforward	22,005,181
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Derecognized [Member]
Non-operating loss carryforward	$ (20,975,994)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Effective Income Tax Rate Reconciliation Combined Federal and Provincial Statutory Income Tax Rate Percent	23.00%	28.00%
Expiration in fiscal year	2035
Derecognize of asset	$ 21,000,000
Decrease in carryforward	$ 7,200,000
Description of agreement	deferred tax liabilities of $6.2 million, were recorded related to a step up of book basis in definite-lived intangible assets recorded in purchase accounting as described in Note 5, Business Combination.
Withholding taxes on royalties	$ 265,000
Stock Purchase Agreement [Member]
Description of agreement	acquire 100% of the equity of Branford PVT Mid-Hold, LLC, of which PulseVet is a wholly owned subsidiary.
Canada [Member]
Net operating loss carryforwards	$ 37,300,000
US [Member]
Net operating loss carryforwards	$ 28,100,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Seraph Biosciences, Inc. [Member]	May 10, 2018USD ($)
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Cash	$ 3,500,000
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Equity	$ 3,500,000

Segmented Information (Details)

Segmented Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating (loss) income	$ (21,367,997)	$ (16,764,978)
(Loss) income before income taxes	(20,716,224)	(16,911,784)
Assets	280,399,293	$ 66,144,034
Revenue	4,133,123
Diagnostics [Member]
Operating (loss) income	(22,414,463)
Net interest income	347,611
Other (gains)	(47,929)
(Loss) income before income taxes	(21,740,247)
Assets	199,556,729
Depreciation and amortization	425,981
Capital expenditures	523,656
Revenue	125,361
Therapeutics [Member]
Operating (loss) income	1,046,466
Net interest income	3,782
Other (gains)	3,932
(Loss) income before income taxes	1,024,023
Assets	80,842,564
Depreciation and amortization	713,608
Capital expenditures	2,293
Revenue	4,007,762
Total [Member]
Operating (loss) income	(21,367,997)
Net interest income	351,393
Other (gains)	(51,861)
(Loss) income before income taxes	(20,716,224)
Assets	280,399,293
Depreciation and amortization	1,139,589
Capital expenditures	525,949
Revenue	$ 4,133,123

Segmented Information (Details

Segmented Information (Details 1) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Right-of-use asset	$ 1,319,810	$ 1,318,716
Property and equipment	1,205,546	583,007
Assets	280,399,293	66,144,034
Canada [Member]
Assets	170,601,082	53,160,701
US [Member]
Assets	$ 109,798,211	$ 12,983,333

Loss Per Share (Details)

Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidated Balance Sheets
Net loss	$ (18,383,170)	$ (16,911,784)
Charge to retained earnings for preferred share exchange	$ (32,038,603)	$ 0
Denominator	956,533,761	364,444,664
Denominator for diluted loss per share (in shares)	956,533,761	364,444,664
Loss per share - basic and diluted	$ (0.05)	$ (0.05)

Loss Per Share (Details Narrati

Loss Per Share (Details Narrative) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 21, 2020
Sharebased Payment Arrangement Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	50,717,724	39,604,515
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	912,418	202,020,823